Document:

Exhibit 10.9

 

 

 

     

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

CONTRACT
TABLE OF CONTENTS

 

	PART I - THE SCHEDULE	4
	SECTION
    B - SUPPLIES OR SERVICES AND PRICES/COSTS	4
	ARTICLE B.1.
    BRIEF DESCRIPTION OF SUPPLIES OR SERVICES	4
	ARTICLE B.2.
    PRICES	4
	ARTICLE B.3.
    ADVANCE UNDERSTANDINGS	4
	SECTION
    C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	5
	ARTICLE C.1.
    STATEMENT OF WORK	5
	ARTICLE C.2.
    REPORTING REQUIREMENTS	5
	ARTICLE C.3.
    INVENTION REPORTING REQUIREMENT	9
	SECTION
    D - PACKAGING, MARKING AND SHIPPING	10
	SECTION
    E - INSPECTION AND ACCEPTANCE	10
	SECTION
    F - DELIVERIES OR PERFORMANCE	10
	ARTICLE F.1.
    PERIOD OF PERFORMANCE	10
	ARTICLE F.2.
    DELIVERIES	10
	ARTICLE F.3.
    CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)	11
	SECTION
    G - CONTRACT ADMINISTRATION DATA	12
	ARTICLE G.1.
    CONTRACTING OFFICER'S REPRESENTATIVE (COR)	12
	ARTICLE G.2.
    KEY PERSONNEL, HHSAR 352.237-75 (December 2015)	12
	ARTICLE G.3.
    INVOICE SUBMISSION	12
	ARTICLE G.4.
    PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (December 2013)	14
	ARTICLE G.5.
    POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE	14
	SECTION
    H - SPECIAL CONTRACT REQUIREMENTS	14
	ARTICLE H.1.
    HUMAN SUBJECTS	14
	ARTICLE H.2. NIH
    POLICY ON ENHANCING REPRODUCIBILITY THROUGH RIGOR AND TRANSPARENCY	15
	ARTICLE H.3.
    NIH POLICY ON ENHANCING PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM NIH-FUNDED RESEARCH	15
	ARTICLE H.4.
    ACKNOWLEDGEMENT OF FEDERAL FUNDING	15
	ARTICLE H.5.
    DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION	15
	ARTICLE H.6.
    CARE OF LIVE VERTEBRATE ANIMALS, HHSAR 352.270-5(b) (December 2015)	15
	ARTICLE H.7.
    ANIMAL WELFARE	16
	ARTICLE H.8.
    RESTRICTION FROM USE OF LIVE VERTEBRATE ANIMALS	16
	ARTICLE H.9.
    RESTRICTION ON PORNOGRAPHY ON COMPUTER NETWORKS	16
	ARTICLE H.10.
    GUN CONTROL	16
	ARTICLE H.11.
    LIMITATIONS ON SUBCONTRACTING - SBIR	17
	ARTICLE H.12. ELECTRONIC
    AND INFORMATION TECHNOLOGY ACCESSIBILITY, HHSAR 352.239-74 (December 2015)	17
	ARTICLE H.13.
    PUBLICATION AND PUBLICITY	17
	ARTICLE H.14.
    REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE	18
	PART II - CONTRACT CLAUSES	19
	SECTION
    I - CONTRACT CLAUSES	19
	PART III - LIST OF DOCUMENTS,
    EXHIBITS AND OTHER ATTACHMENTS	23

 

    	 	- 2 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

	SECTION
    J - LIST OF ATTACHMENTS	23
	1. Statement
    of Work	23
	2. Invoice Instructions
    for NIH Fixed-Price Contracts, NIH(RC)-2	23
	3. Safety and
    Health	23
	4. Disclosure
    of Lobbying Activities, SF-LLL	23
	5. NIH Small
    Business Innovation Research (SBIR) Program Funding Agreement Certification	23
	6. NIH Small
    Business Innovation Research (SBIR) Program Life Cycle Certification	23
	PART IV - REPRESENTATIONS AND
    INSTRUCTIONS	24
	SECTION
    K - REPRESENTATIONS AND CERTIFICATIONS	24
	1. Annual Representations
    and Certifications	24
	2. Animal Welfare
    Assurance Number	24

 

    	 	- 3 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

PART
I - THE SCHEDULE 

 

SECTION
B - SUPPLIES OR SERVICES AND PRICES/COSTS 

 

ARTICLE
B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

 

In this Phase
I project the objectives are to develop and annotate AA prostate epithelial cancer cell line with donor matched normal prostate
epithelial cells and bio-banked reference prostate tissues. Also to support the feasibility of establishing 50 prostate cancer
cell lines from AA men in a subsequent Phase II application, prepare written protocols for tissue collection, processing, establishment
of conditionally reprogrammed cells and the reagents necessary for performing studies with these cells.

 

ARTICLE
B.2. PRICES

 

		a.	The
                                         total fixed price of this contract is $224,687.

 

		b.	Upon
                                         delivery and acceptance of the item(s) and/or service(s) specified in the DELIVERY Article
                                         in SECTION F and described in SECTION C of this contract and identified in the schedule
                                         of charges below, the Government shall pay to the Contractor the unit prices set forth
                                         below:

 

PAYMENT
SCHEDULE

 

	Description	 	Invoice #	 	Period Covered	 	Amount	 
	PDF Kick-Off Presentation	 	HHSN261201600038C - 01	 	Month 1	 	$	50,000	 
	Quarterly Report 1	 	HHSN261201600038C - 02	 	Months 1-3	 	$	50,000	 
	Quarterly Report 2	 	HHSN261201600038C - 03	 	Months 4-6	 	$	50,000	 
	Draft Final Report	 	HHSN261201600038C - 04	 	Effective date of contract through one month prior to completion date of contract	 	$	37,344	 
	Final Report, Contract Outcomes Report, Final Presentation, and all other contract deliverables	 	HHSN261201600038C - 05	 	Entire Period of Performance of contract	 	$	37,343	 
	TOTAL FIXED PRICE	 	 	 	 	 	$	224,687	 

 

ARTICLE
B.3. ADVANCE UNDERSTANDINGS

 

Other provisions
of this contract notwithstanding, approval of the following items within the limits set forth is hereby granted without further
authorization from the Contracting Officer.

 

		a.	Establishment
of Indirect Cost Rate

 

Fringe
Benefits costs are funded at a rate of 15% of Total Direct Labor Costs; Overhead costs are funded at a rate of 39% of Total Direct
Labor and Fringe Benefits Costs; G&A is funded at a rate of 12% of Total Direct Labor and Fringe Benefits Costs; however,
the Contractor shall not bill or be reimbursed for indirect costs until such time as an indirect cost proposal has been submitted
to the cognizant office responsible for negotiating the indirect cost rates, unless a temporary billing rate(s) has been included
herein. Unless otherwise specified below, the indirect cost rate proposal shall be submitted no later than three (3) months after
the date of contract award.

 

    	 	- 4 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		b.	Subcontract

 

To negotiate a
fixed price type subcontract with Georgetown University for Cell and Animal-Based Models to Advance Health Disparity Research
for an amount not to exceed $70,129 for the period 9/19/2016 through 6/18/2017. Award of the subcontract shall not proceed without
the prior written consent of the Contracting Officer upon review of the supporting documentation required by FAR Clause 52.244-2,
Subcontracts. After receiving written consent of the subcontract by the Contracting Officer, a copy of the signed, executed subcontract
shall be provided to the Contracting Officer.

 

		c.	Contract
Number Designation

 

On all correspondence
submitted under this contract, the Contractor agrees to clearly identify the two contract numbers that appear on the face page
of the contract as follows:

 

Contract No. HHSN261201600038C
..

 

NCI Control No.
N43CO-2016-00038 .

 

		d.	SBIR
Funding Agreement Certification

 

The
SBIR Funding Agreement Certification form, located in SECTION J, must be completed at the time of award prior to the performance
of work under this contract, in accordance with the SBIR Policy Directive issued by SBA (October 18, 2012).

 

For
additional information, see NIH Policy Notice NOT-OD-13-116, entitled, "New Program Certifications Required for SBIR and
STTR Awards," located at: http://grants.nih.gov/grants/guide/notice-files/NOT- OD-13-116.html.

 

SECTION
C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT 

 

ARTICLE
C.1. STATEMENT OF WORK

 

		a.	Independently
and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material,
equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work, dated September
19, 2016, set forth in SECTION J-List of Attachments, attached hereto and made a part of this contract.

 

ARTICLE
C.2. REPORTING REQUIREMENTS

 

All
reports required herein shall be submitted in electronic format via e-mail, as attachments, to the following designated NCI Branch
Distribution Mailbox: NCIbrancheinvoices@mail.nih.gov.

 

Each
e-mail submission shall contain only one deliverable. If the attached file for the deliverable exceeds 50 MB, the Contractor shall
divide the deliverable into files of 50 MB each. All deliverables shall be limited to five file attachments or less.

 

The
subject line of the e-mail shall read as follows: Deliverable_Contract Number_Vendor's Name_Deliverable Description_Due Date.

 

All
electronic reports submitted shall be compliant with Section 508 of the Rehabilitation Act of 1973. Additional information about
testing documents for Section 508 compliance, including guidance and specific checklists, by application, can be found at: http://www.hhs.gov/web/508/index.html
under "Making Files Accessible."

 

    	 	- 5 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		a.	Technical
Reports

 

In
addition to those reports required by the other terms of this contract, the Contractor shall prepare and submit the following
reports in the manner stated below and in accordance with the DELIVERIES Article in SECTION F of this contract:

 

[Note:
The Contractor shall include, in any technical progress report submitted, the applicable PubMed Central (PMC) or NIH Manuscript
Submission reference number when citing publications that arise from its NIH funded research.]

 

		1.	Kick-Off
Presentation

 

The Contractor
shall prepare and submit a kick-off presentation. Slides shall be prepared and presentation of the slides shall occur either in-person
or through webinar or teleconference. The presentation shall cover the following:

 

		a.	Discussion
of the Contractor's organization and project status, particularly changes that occurred since the proposal submission;

 

		b.	Contractor's
recent achievements (patents, publications, sales, regulatory approvals, partnerships, awards, etc.);

 

		c.	Status
of the field;

 

		d.	Status
of commercial and academic competitors;

 

		e.	Where
the proposed project is positioned against the state of the art;

 

		f.	Intellectual
property landscape;

 

		g.	Refresher
on the proposed technology/R&D;

 

		h.	Detailed
plan for the first budget period of the contract;

 

		i.	Milestones
(technical and commercial) to be achieved by the end of the first budget period of the contract;

 

		j.	Discussion of anticipated technical risks and alternative
approaches; 
	 	 	 
	 	k. 	Questions to the NCI.

 

		2.	Quarterly
Reports

 

The
Contractor shall submit Quarterly Reports, which shall include:

 

		a.	Summary of technical objectives with
                                                                               status of each objective clearly marked ( e.g. previously completed, completed during this reporting period, not
                                                                               started, etc);

 

		b.	Clear
description of activities accomplished in the quarter;

 

		c.	Analysis
of experimental data and presentation of selected data;

 

		d.	Comments
regarding the timeliness of performance;

 

		e.	Brief
explanation of objectives/activities to be pursued in the next reporting period.

 

This report shall
generally be no longer than five (5) pages, excluding tables, figures, images and graphs used to present data.

 

    	 	- 6 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		3.	Draft
Final Report

 

The Contractor
shall submit a Draft Final Report. The Government Contracting Officer's Representative (COR) will review and provide comments
on the Draft Final Report, which the Contractor shall incorporate into a revised Final Report ( - see Reporting Requirement Item
4).

 

The Draft Final
Report shall include the following three sections:

 

Section 1:
Summary of Salient Results

 

The Summary of
Salient Results shall summarize in 200 words or less the salient results achieved during performance of the contract.

 

Section 2:
Final Technical Report

 

The Final Technical
Report shall set forth the work performed and results obtained for the entire contract period of performance. This report shall
be in sufficient detail to describe comprehensively the results achieved.

 

Section 3:
Draft Commercialization Plan

 

		a.	Value of the SBIR Project, Expected Outcomes, and
Impact

 

Describe,
in layperson's terms, the proposed project and its key technology objectives. State the product, process, or service to be developed
in Phases II and III. Clarify the need addressed, specifying weaknesses in the current approaches to meet this need. In addition,
describe the commercial applications of the research and the innovation inherent in this application. Be sure to also specify
the potential societal, educational, and scientific benefits of this work. Explain the non-commercial impacts to the overall significance
of the project. Explain how the SBIR contract integrates with the overall business plan of the company.

 

		b.	Organization

Give a brief description
of the Contractor's organization, including corporate objectives, core competencies, present size (annual sales level and number
and types of employees), history of previous Federal and non-Federal funding, regulatory experience and subsequent commercialization,
and any current products/services that have significant sales. Include a short description of the origins of the Contractor's
organization. Indicate the Contractor's vision for the future, how the Contractor will grow/maintain a sustainable business entity,
and how the Contractor will meet critical management functions as the Contractor's organization evolves from a small technology
R&D business to a successful commercial entity.

 

		c.	Market, Customer, and Competition

Describe the market
and/or market segments being targeted and provide a brief profile of the potential customer. Tell what significant advantages
the Contractor's innovation will bring to the market - e.g., better performance, lower cost, faster, more efficient or
effective, new capability. Explain the hurdles the Contractor will have to overcome in order to gain market/customer acceptance
of the Contractor's innovation. Describe any strategic alliances, partnerships, or licensing agreements the Contractor has in
place to get FDA approval (if required) and to market and sell the Contractor's product. Briefly describe the Contractor's marketing
and sales strategy. Give an overview of the current competitive landscape and any potential competitors over the next several
years.

 

		d.	Intellectual Property (IP) Protection

Describe how the
Contractor is going to protect the IP that results from the Contractor's innovation. Also, note other actions the Contractor may
consider taking that will constitute at least a temporal barrier to others aiming to provide a solution similar to the Contractor's.

 

    	 	- 7 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		e.	Finance Plan

Describe
the necessary financing the Contractor will require to commercialize the product, process, or service, and when it will be required.
Describe the Contractor's plans to raise the requisite financing to launch the Contractor's innovation into Phase Ill and begin
the revenue stream. Plans for this financing stage may be demonstrated in one or more of the following ways:

 

		•	Letter
of commitment of funding.

 

		•	Letter
of intent or evidence of negotiations to provide funding, should the Phase II project be successful and the market need still
exist.

 

		•	Letter
of support for the project and/or some in-kind commitment, e.g., to test or evaluate the innovation.

 

		•	Specific
steps the Contractor is going to take to secure Phase III funding.

 

		f.	Production and Marketing Plan

Describe
how the production of the Contractor's product/process/service will occur ( e.g., in- house manufacturing, contract manufacturing).
Describe the steps the Contractor will take to market and sell the Contractor's product/process/service. For example, explain
plans for licensing, Internet sales, etc.

 

		g.	Revenue Stream

Explain how the
Contractor plans to generate a revenue stream for the Contractor's organization should this project be a success. Examples of
revenue stream generation include, but are not limited to; manufacture and direct sales, sales through value added resellers or
other distributors, joint venture, licensing, service. Describe how the Contractor's staffing will change to meet the Contractor's
revenue expectations.

 

		4.	Final
Report

 

The Contractor
shall submit a Final Report. This document shall incorporate revisions in response to the comments provided by the Government
COR after review of the Draft Final Report ( - see Reporting Requirements Item 3).

 

		5.	Contract
Outcomes Report

 

The
Contractor shall submit a Contract Outcomes Report using a fillable PDF form to be provided by the Government. The Contract Outcomes
Report must be provided as a filled-in version of the PDF form provided and not as a printed or scanned copy of this document.

 

		6.	Final
Presentation

 

The Contractor
shall prepare and submit a final presentation. Slides shall be prepared and presentation of the slides shall occur either in-person
or through webinar or teleconference. The presentation shall cover the following:

 

		a.	Discussion
of the Contractor's organization and project status;

 

		b.	Contractor's
achievements during the performance period (patents, publications, sales, regulatory approvals, partnerships, awards, etc.);

 

		c.	Detailed
results of the performed research and development;

 

    	 	- 8 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		d.	Discussion
of proposed milestones and whether they were achieved during the contract performance;

 

		e.	Summary
of submitted commercialization plan;

 

		f.	Discussion
of the anticipated Phase II activities with emphasis on how they fit into the commercialization plan, if Contractor is interested
in pursuing Phase II research;

 

		g.	Questions
to the NCI.

 

		b.	Other
Reports/Deliverables

 

		1.	Section
                                         508 Annual Report

 

The contractor
shall submit an annual Section 508 report in accordance with the schedule set forth in the ELECTRONIC AND INFORMATION TECHNOLOGY
ACCESSIBILITY Article in SECTION H of this contract. The Section 508 Report Template and Instructions for completing the report
are available at: http://www.hhs.gov/web/508/contracting/technology/vendors.html under "Vendor Information and Documents."

 

		2.	NIH
                                         Small Business Innovation Research (SBIR) Program Life Cycle Certification

 

In
accordance with the SBIR/STTR Reauthorization Act of 2011, the contractor shall complete and submit the NIH Small Business Innovation
Research (SBIR) Life Cycle Certification form, located in SECTION J, of the contract to the Contracting Officer. This certification
is required to ensure the contractor is meeting the program's requirements during the life cycle of the contract.

 

The
Life Cycle Certification form shall be submitted as follows:

 

		•	Phase
I SBIR Contractors shall submit the Certification at the time of receiving final payment or disbursement.

 

		•	Phase
                                         II SBIR Contractors shall submit the Certification prior to receiving more than 50% of
                                         the total contract amount AND prior to final payment or disbursement.

 

The Contracting
Officer, may, at any time after ward request further clarifications and supporting documentation in order to assist in the verification
of any information provided by the contractor.

 

For
additional information, see NIH Policy Notice NOT-OD-13-116, entitled, "New Program Certifications Required for SBIR and
STTR Awards, " located at: http://grants.nih.gov/grants/guide/ notice-files/NOT-OD-13-116.html.

 

ARTICLE
C.3. INVENTION REPORTING REQUIREMENT

 

All reports and
documentation required by FAR Clause 52.227-11, Patent Rights-Ownership by the Contractor including, but not limited to, the invention
disclosure report, the confirmatory license, and the Government support certification, shall be directed to the Division of Extramural
Inventions and Technology Resources (DEITR), OPERA, OER, NIH, 6705 Rockledge Drive, Suite 310, MSC 7980, Bethesda, Maryland 20892-7980
(Telephone: 301-435-1986). In addition, one copy of an annual utilization report, and a copy of the final invention statement,
shall be submitted to the Contracting Officer. The final invention statement (see FAR 27.303(b)(2)(ii)) shall be submitted to
the Contracting Officer on or before the completion date of the contract.

 

If no invention
is disclosed or no activity has occurred on a previously disclosed invention during the applicable reporting period, a negative
report shall be submitted to the Contracting Officer via e-mail.

 

    	 	- 9 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

To assist contractors
in complying with invention reporting requirements of the clause, the NIH has developed "Interagency Edison," an electronic
invention reporting system. Use of Interagency Edison is required as it streamlines the
reporting process and greatly reduces paperwork. Access to the system is through a secure interactive Web site to ensure that
all information submitted is protected. Interagency Edison and information relating to the capabilities of the system can be obtained
from the Web ( http://www.iedison.gov), or by contacting
the Extramural Inventions and Technology Resources Branch, OPERA, NIH.

 

SECTION
D - PACKAGING, MARKING AND SHIPPING

 

All
deliverables required under this contract shall be packaged, marked and shipped in accordance with Government specifications.
At a minimum, all deliverables shall be marked with the contract number and Contractor name. The Contractor shall guarantee that
all required materials shall be delivered in immediate usable and acceptable condition.

 

SECTION
E - INSPECTION AND ACCEPTANCE

 

		a.	The
Contracting Officer or the duly authorized representative will perform inspection and acceptance of materials and services to
be provided.

 

		b.	For
the purpose of this SECTION, the Contracting Officer's Representative (COR) is the authorized representative of the Contracting
Officer.

 

		c.	Inspection
and acceptance will be performed at:

 

National
Cancer Institute 

9609 Medical Center Drive 

Rockville, MD 20850

 

Acceptance may
be presumed unless otherwise indicated in writing by the Contracting Officer or the duly authorized representative within 30 days
of receipt.

 

		d.	This
contract incorporates the following clause by reference, with the same force and effect as if it were given in full text. Upon
request, the Contracting Officer will make its full text available.

 

FAR
Clause 52.246-9, Inspection of Research and Development (Short Form) (April 1984).

 

FAR
Clause 52.246-16, Responsibility for Supplies (April 1984).

 

SECTION
F - DELIVERIES OR PERFORMANCE

 

ARTICLE F.1. PERIOD OF PERFORMANCE

 

The
period of performance of this contract shall be from 09/19/2016 through 06/18/2017.

 

ARTICLE
F.2. DELIVERIES

 

Satisfactory
performance of the final contract shall be deemed to occur upon performance of the work described in the Statement of Work Article
in SECTION C of this contract and upon delivery and acceptance by the Contracting Officer, or the duly authorized representative,
of the following items in accordance with the stated delivery schedule:

 

		a.	The
items specified below as described in the REPORTING REQUIREMENTS Article in SECTION C of this contract will be required to be
delivered F.o.b. Destination as set forth in FAR 52.247-35, F.o.b. DESTINATION, WITHIN CONSIGNEES PREMISES (APRIL 1984), and in
accordance with and by the date(s) specified below:

 

    	 	- 10 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

	Item	 	Description	 	Delivery
    Schedule
	(1)	 	SBIR
    Funding Agreement Certification	 	Due
    at time of award, prior to performance of any work under this contract.
	(2)	 	Kick-Off
    Presentation	 	Due
    on or before 30 calendar days following the effective date of the contract.
	(3)	 	Quarterly
    Report One	 	Due
    on or before 15 calendar days following completion of 3 full months of contract performance.
	(4)	 	Quarterly
    Report Two	 	Due
    on or before 15 calendar days following completion of 6 full months of contract performance.
	(5)	 	Draft
    Final Report	 	Due
    on or before 1 month prior to the contract completion date.
	(6)	 	Final
    Report	 	Due
    on or before the contract completion date.
	(7)	 	Contract
    Outcomes Report	 	Due
    on or before the contract completion date.
	(8)	 	Final
    Presentation	 	Due
    on or before the contract completion date.
	(9)	 	Final
    Invention Statement	 	Due
    on or before the contract completion date.
	(10)	 	Invention
    Disclosure Report	 	Due
    on or before the contract completion date.
	(11)	 	SBIR
    Program Life Cycle Certification	 	Due
    on or before the contract completion date.
	(12)	 	Section
    508 Annual Report	 	Due on or before
    the contract completion date.

 

		b.	The
                                         above items shall be addressed and delivered to ncibrancheinvoices@mail.nih.gov,
                                         as well as to the following addressees:

 

	Addressee
	 	Deliverables
	Kathleen
    Sears	 	All
    deliverables, in electronic format.
	Office
    of Acquisitions	 	 
	searsky@mail.nih.gov	 	 
	Todd
    Haim	 	All
    deliverables, in electronic format.
	NCI SBIR
    & STTR Programs	 	 
	Haimte@mail.nih.gov	 	 
	OPERA,
    OEH, NIH	 	Items
    9 and 10, in hard copy.
	6705 Rockledge
    Drive	 	 
	Suite
    310, MSC 7980	 	 
	Bethesda,
    MD 20892-7980	 	 

 

ARTICLE
F.3. CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)

 

This
contract incorporates the following clause(s) by reference, with the same force and effect as if it were given in full text. Upon
request, the Contracting Officer will make its full text available. Also, the full text of a clause may be accessed electronically
at this address: http://www.acquisition.gov/far.

 

FEDERAL
ACQUISITION REGULATION (48 CFR CHAPTER 1) CLAUSE:

 

52.242-15,
Stop Work Order (August 1989)

 

Alternate
I (April 1984) is not applicable to this contract.

 

    	 	- 11 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

SECTION
G - CONTRACT ADMINISTRATION DATA

 

ARTICLE
G.1. CONTRACTING OFFICER'S REPRESENTATIVE (COR)

 

The following Contracting Officer's Representative (COR) will represent the Government for the purpose of this contract:

 

Todd Haim

 

The COR is
responsible for: (1) monitoring the Contractor's technical progress, including the surveillance and assessment of performance
and recommending to the Contracting Officer changes in requirements; (2) interpreting the statement of work and any other technical
performance requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances
required by this contract; and (5) assisting in the resolution of technical problems encountered during performance.

 

The Contracting
Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer
has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance;
(3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any costs incurred during the performance
of this contract; (5) otherwise change any terms and conditions of this contract; or (6) sign written licensing agreements. Any
signed agreement shall be incorporated by reference in Section K of the contract

 

The Government
may unilaterally change its COR designation.

 

ARTICLE
G.2. KEY PERSONNEL, HHSAR 352.237-75 (December 2015)

 

The key personnel
specified in this contract are considered to be essential to work performance. At least 30 days prior to the contractor voluntarily
diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer
and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify
the proposed replacement and provide an explanation of how the replacement's skills, experience, and credentials meet or exceed
the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the contractor
is terminated for cause or separates from the contractor voluntarily with less than thirty days notice, the Contractor shall provide
the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change
to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel
as necessary to reflect the agreement of the parties.

 

(End of Clause)

 

The following individual(s) is/are considered to be essential to the work being performed hereunder:

 

	Name	 	Title
	Dr.
    Johng Rhim	 	Principal Investigator

 

ARTICLE G.3. INVOICE SUBMISSION

 

		a.	Invoice Instructions for NIH Fixed-Price Type Contracts,
NIH(RC)-2, are attached and made part of this contract. The Contractor shall follow the attached instructions and submission procedures
specified below to meet the requirements of a "proper invoice" pursuant to FAR Subpart 32.9, Prompt Payment.

 

		1.	Payment requests shall be submitted to the offices
identified below. Do not submit supporting documentation (e.g., receipts, time sheets, vendor invoices, etc.) with your payment
request unless specified elsewhere in the contract or requested by the Contracting Officer.

 

    	 	- 12 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		a.	The
original invoice shall be submitted to the following designated billing office:

 

National Institutes
of Health 

Office of Financial Management 

Commercial Accounts

2115 East Jefferson
Street, Room 4B-432, MSC 8500

 Bethesda, MD 20892-8500

 

		b.	One
courtesy copy of the original invoice shall be submitted electronically as follows:

 

		1.	The
Contractor shall scan the original payment request (invoice) in Adobe Portable Document Format (PDF) along with the necessary
supporting documentation as one single attachment.

 

		2.	Save
                                         the single attachment (scanned invoice along with any supporting documentation) in
                                         the following format: YourVendorName_Invoice number (e.g., if you are submitting Invoice
                                         123456, save the single attachment as "Ash Stevens_Invoice 123456") [Note:
                                         Please do not use special characters such as (#, $, %,*, &, !) when saving your attachment.
                                         Only the underscore symbol (_) is permitted.]

 

		3.	Transmit
                                         the saved single attachment via e-mail to the appropriate branch's Central Point
                                         of Distribution. For the purpose of this contract, the Central Point of Distribution
                                         is NCI OA Branch E - ncibrancheinvoices@mail.nih.gov. Only one payment request
                                         shall be submitted per e-mail and the subject line of the e-mail shall include the Contract
                                         Number_ Contract Title_ Contractor's Name_ unique Invoice number

 

(e.g,
HHSN2612XXXXXC_Clinical Genetics Support_Ash Stevens_Invoice 12345) [Note: The original payment request must still be submitted
in hard copy and mailed to the designated billing office listed in subparagraph a, above, to meet the requirements of a "proper
invoice." Also, The Contractor must certify on the payment request that the electronic courtesy copy is a duplicate of the
original invoice mailed to NIH's Office of Financial Management.]

 

		2.	In
addition to the requirements specified in FAR 32.905 for a proper invoice, the Contractor shall include the following information
on the face page of all payment requests:

 

		a.	Name
of the Office of Acquisitions. The Office of Acquisitions for this contract is National Cancer Institute .

 

		b.	Federal
Taxpayer Identification Number (TIN). If the Contractor does not have a valid TIN, it shall identify the Vendor Identification
Number (VIN) on the payment request. The VIN is the number that appears after the Contractor's name on the face page of the contract.
If the Contractor has neither a TIN, DUNS, or VIN, contact the Contracting Officer.

 

		c.	DUNS
or DUNS+4 Number. The DUNS number must identify the Contractor's name and address exactly as stated in the contract and as registered
in the Central Contractor Registration (CCR) database. If the Contractor does not have a valid DUNS number, it shall identify
the Vendor Identification Number (VIN) on the payment request. The VIN is the number that appears after the Contractor's name
on the face page of the contract. If the Contractor has neither a TIN, DUNS, or VIN, contact the Contracting Officer.

 

		d.	Invoice
Matching Option. This contract requires a two-way match.

 

    	 	- 13 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		e.	Unique
Invoice Number. Each payment request must be identified by a unique invoice number, which can only be used one time regardless
of the number of contracts or orders held by an organization.

 

		f.	The
contract period of performance.

 

		g.	The
contract title.

 

		b.	Inquiries
regarding payment of invoices shall be directed to the designated billing office, (301) 496-6452.

 

ARTICLE
G.4. PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (December 2013)

 

		a.	Upon
receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors
under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable
contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor.

 

		b.	The
acceleration of payments under this clause does not provide any new rights under the prompt Payment Act.

 

		c.	Include
the substance of this clause, include this paragraph c, in all subcontracts with small business concerns, including subcontracts
with small business concerns for the acquisition of commercial items.

 

(End of Clause)

 

ARTICLE
G.5. POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE

 

		a.	Contractor Performance Evaluations

 

A Final evaluation
of Contractor performance will be prepared on this contract in accordance with FAR Subpart 42.15. The Final performance evaluation
will be prepared at the time of completion of work.

 

The Final evaluation
will be provided to the Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted
thirty days to review the document and to submit additional information or a rebutting statement. If agreement cannot be reached
between the parties, the matter will be referred to an individual one level above the Contracting Officer, whose decision will
be final.

 

Copies of the
evaluation, Contractor responses, and review comments, if any, will be retained as part of the contract file, and may be used
to support future award decisions.

 

		b.	Electronic Access to Contractor Performance Evaluations

 

Contractors may
access evaluations through a secure Web site for review and comment at the following address:

 

http://www.cpars.gov

 

SECTION H - SPECIAL CONTRACT REQUIREMENTS

 

ARTICLE H.1. HUMAN SUBJECTS

 

It
is hereby understood and agreed that research involving human subjects shall not be conducted under this contract, and that no
material developed, modified, or delivered by or to the Government under this contract, or any subsequent modification of such
material, will be used by the Contractor or made available by the Contractor for use by anyone other than the Government, for
experimental or therapeutic use involving humans without the prior written approval of the Contracting Officer.

 

    	 	- 14 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

ARTICLE
H.2. NIH POLICY ON ENHANCING REPRODUCIBILITY THROUGH RIGOR AND TRANSPARENCY

 

Contractors shall
adhere to the NIH policy of enhancing reproducibility through rigor and transparency by addressing each of the four areas of the
policy in performance of the Statement of Work and in publications, as applicable:

1)
Scientific Premise; 2) Scientific Rigor; 3) Consideration of Relevant Biological Variables, including Sex; and 4) Authentication
of Key Biological and/or Chemical Resources. This policy applies to all NIH funded research and development, from basic through
advanced clinical studies. See NIH Guide Notice, NOT-OD-15-103, "Enhancing Reproducibility through Rigor and Transparency"
and NOT-OD-15-102, "Consideration of Sex as a Biological Variable in NIH-funded Research" for more information.
In addition, publications are expected to follow the guidance at http:// www.nih.gov/research-training/rigor-reproducibility/principles-guidelines-reporting-preclinical-research,
whether preclinical or otherwise, as appropriate. More information is available at http://grants.nih.gov/reproducibility/index.htm,
including FAQs and a General Policy Overview.

 

ARTICLE
H.3. NIH POLICY ON ENHANCING PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM NIH-FUNDED RESEARCH

 

NIH-funded
investigators shall submit to the NIH National Library of Medicine's (NLM) PubMed Central (PMC) an electronic version of the author's
final manuscript, upon acceptance for publication, resulting from research supported in whole or in part with direct costs from
NIH. NIH defines the author's final manuscript as the final version accepted for journal publication, and includes all modifications
from the publishing peer review process. The PMC archive will preserve permanently these manuscripts for use by the public, health
care providers, educators, scientists, and NIH. The Policy directs electronic submissions to the NIH/NLM/PMC: http://www.pubmedcentral.nih.gov.

 

Additional
information is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-071.html and http://
publicaccess.nih.gov.

 

ARTICLE
H.4. ACKNOWLEDGEMENT OF FEDERAL FUNDING

 

The Contractor
shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations and other documents describing
projects or programs funded in whole or in part with Federal money: (1) the percentage of the total costs of the program or project
which will be financed with Federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage
and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources.

 

ARTICLE
H.5. DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION

 

The Contractor
shall not use contract funds to disseminate information that is deliberately false or misleading.

 

ARTICLE
H.6. CARE OF LIVE VERTEBRATE ANIMALS, HHSAR 352.270-5(b) (December 2015)

 

		a.	Before
undertaking performance of any contract involving animal-related activities where the species is regulated by the United Sates
Department of Agriculture (USDA), the Contractor shall register with the Secretary of Agriculture of the United States in accordance
with 7 U.S.C. 2136 and 9 CFR 2.25 through 2.28. The Contractor shall furnish evidence of the registration to the Contracting Officer.

 

		b.	The
Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C.
2133 and 9 CFR 2.1 2.11, or from a source that is exempt from licensing under those sections.

 

		c.	The
Contractor agrees that the care, use, and intended use of any live vertebrate animals in the performance of this contract shall
conform with the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals (PHS Policy), the current Animal
Welfare Assurance (Assurance), the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and
the pertinent laws and regulations of the United States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR subchapter
A, Parts 1-4). In case of conflict between standards, the more stringent standard shall govern.

 

    	 	- 15 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		d.	If at any time during performance of
                                                                                  this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW),
                                                                                  National Institutes of Health (NIH), that the Contractor is not in compliance with any of the requirements and standards
                                                                                  stated in paragraphs (a) through (c) above, the Contracting Officer may immediately suspend, in whole or in part, work and
                                                                                  further payments under this contract until the Contractor corrects the noncompliance. Notice of the suspension may
                                                                                  be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action within the
                                                                                  period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer may, in
                                                                                  consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor's name may be removed from the
                                                                                  list of those contractors with Animal Welfare Assurances.

 

Note:
The Contractor may request registration of its facility and a current listing of licensed dealers from the Regional Office of
the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility is located. The location
of the appropriate APHIS Regional Office, as well as information concerning this program may be obtained by contacting the Animal
Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737 (Email: ace@aphis.usda.gov;
Web site: ( http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/animalwelfare).

 

(End of clause)

 

ARTICLE
H.7. ANIMAL WELFARE

 

All
research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care
and Use of Laboratory Animals (PHS Policy). The PHS Policy can be accessed at: http://grants1.nih.gov/grants/olaw/references/phspol.htm

 

In
addition, the research involving live vertebrate animals shall be conducted in accordance with the description set forth in the
Vertebrate Animal Section (VAS) of the contractor's technical proposal, as modified in the Final Proposal Revision (FPR), dated
9/19/2016, which is incorporated by reference.

 

ARTICLE
H.8. RESTRICTION FROM USE OF LIVE VERTEBRATE ANIMALS

 

UNDER GOVERNING
POLICY, FEDERAL FUNDS ADMINISTERED BY THE PUBLIC HEALTH SERVICE (PHS) SHALL NOT BE EXPENDED FOR RESEARCH INVOLVING LIVE VERTEBRATE
ANIMALS WITHOUT PRIOR APPROVAL BY THE OFFICE OF LABORATORY ANIMAL WELFARE (OLAW), OF [ AN ANIMAL WELFARE ASSURANCE THAT COMPLIES
WITH THE PHS POLICY ON HUMANE CARE AND USE OF LABORATORY ANIMALS AND/OR A VALID INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC)
APPROVAL]. THIS RESTRICTION APPLIES TO ALL PERFORMANCE SITES (e.g. COLLABORATING INSTITUTIONS, SUBCONTRACTORS, SUBGRANTEES)
WITHOUT OLAW-APPROVED ASSURANCES, WHETHER DOMESTIC OR FOREIGN.

 

ARTICLE
H.9. RESTRICTION ON PORNOGRAPHY ON COMPUTER NETWORKS

 

The Contractor
shall not use contract funds to maintain or establish a computer network unless such network blocks the viewing, downloading,
and exchanging of pornography.

 

ARTICLE
H.10. GUN CONTROL

 

The Contractor
shall not use contract funds in whole or in part, to advocate or promote gun control.

 

    	 	- 16 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

ARTICLE
H.11. LIMITATIONS ON SUBCONTRACTING - SBIR

 

The Contractor
shall perform a minimum of two-thirds of the research and/or analytical effort conducted under this contract, as measured by total
contract dollars. Any deviation from this requirement must be approved in writing by the Contracting Officer.

 

ARTICLE
H.12. ELECTRONIC AND INFORMATION TECHNOLOGY ACCESSIBILITY, HHSAR 352.239-74 (December 2015)

 

		a.	Pursuant
to Section 508 of the Rehabilitation Act of 1973(29 U.S.C. 794d), as amended by the Workforce Investment Act of 1998, all electronic
and information technology (EIT) supplies and services developed, acquired, or maintained under this contract or order must comply
with the "Architectural and Transportation Barriers Compliance Board Electronic and Information Technology (EIT) Accessibility
Standards'' set forth by the Architectural and Transportation Barriers Compliance Board (also referred to as the "Access
Board'') in 36 CFR part 1194. Information about Section 508 is available at http://www.hhs.gov/web/508. The complete text
of Section 508 Final Provisions can be accessed at http://www.access-board.gov/guidelines-and-standards/communications-and-it/about-the-section-508-standards.

 

		b.	The
Section 508 accessibility standards applicable to this contract or order are identified in the Statement of Work or Specification
or Performance Work Statement. The contractor must provide any necessary updates to the submitted HHS Product Assessment Template(s)
at the end of each contract or order exceeding the simplified acquisition threshold (see FAR 2.101) when the contract or order
duration is one year or less. If it is determined by the Government that EIT supplies and services provided by the Contractor
do not conform to the described accessibility standards in the contract, remediation of the supplies or services to the level
of conformance specified in the contract will be the responsibility of the Contractor at its own expense.

 

		c.	The
Section 508 accessibility standards applicable to this contract are: None.

 

		d.	In
                                         the event of a modification(s) to this contract or order,which adds new EIT supplies
                                         or services or revises the type of, or specifications for, supplies or services, the
                                         Contracting Officer may require that the contractor submit a completed HHS Section 508
                                         Product Assessment Template and any other additional information necessary to assist
                                         the Government in determining that the EIT supplies or services conform to Section 508
                                         accessibility standards. Instructions for documenting accessibility via the HHS Section
                                         508 Product Assessment Template may be found under Section 508 policy on the HHS Web
                                         site: ( http://www.hhs.gov/web/508).
                                         If it is determined by the Government that EIT supplies and services provided by the
                                         Contractor do not conform to the described accessibility standards in the contract, remediation
                                         of the supplies or services to the level of conformance specified in the contract will
                                         be the responsibility of the Contractor at its own expense.

 

		e.	If
                                         this is an Indefinite Delivery contract, a Blanket Purchase Agreement or a Basic Ordering
                                         Agreement, the task/delivery order requests that include EIT supplies or services will
                                         define the specifications and accessibility standards for the order. In those cases,
                                         the Contractor may be required to provide a completed HHS Section 508 Product Assessment
                                         Template and any other additional information necessary to assist the Government in determining
                                         that the EIT supplies or services conform to Section 508 accessibility standards. Instructions
                                         for documenting accessibility via the HHS Section 508 Product Assessment Template may
                                         be found at http:// www.hhs.gov/web/508.
                                         If it is determined by the Government that EIT supplies and services provided by the
                                         Contractor do not conform to the described accessibility standards in the provided documentation,
                                         remediation of the supplies or services to the level of conformance specified in the
                                         contract will be the responsibility of the Contractor at its own expense.

 

(End
of clause)

 

ARTICLE
H.13. PUBLICATION AND PUBLICITY

 

In addition to
the requirements set forth in HHSAR Clause 352.227-70, Publications and Publicity incorporated by reference in SECTION
I of this contract, the Contractor shall acknowledge the support of the National Institutes of Health whenever publicizing the
work under this contract in any media by including an acknowledgment substantially as follows:

 

    	 	- 17 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

"This
project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health,
Department of Health and Human Services, under Contract No. HHSN261201600038C."

 

ARTICLE
H.14. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE

 

Anyone
who becomes aware of the existence or apparent existence of fraud, waste and abuse in NIH funded programs is encouraged to report
such matters to the HHS Inspector General's Office in writing or on the Inspector General's Hotline. The toll free number is 1-800-HHS-TIPS
(1-800-447-8477). All telephone calls will be handled confidentially. The website to file a complaint on-line is: http://oig.hhs.gov/fraud/hotline/
and the mailing address is:

 

US Department
of Health and Human Services

Office of Inspector
General

ATTN: OIG HOTLINE
OPERATIONS

P.O. Box 23489

Washington, D.C.
20026

 

ARTICLE
H.15. ADVANCED COPIES OF PRESS RELEASES

 

Press releases
shall be considered to include the public release of information to any medium, excluding peer- reviewed scientific publications.
The Contractor shall not publish a press release related to this contract without receiving prior concurrence from the Contracting
Officer (CO). The Contractor shall submit an advance copy of the press release to the Contracting Officer and Contracting Officer's
Representative (COR). Upon acknowledgement of receipt, the Contracting Officer will have five (5) working days to respond with
concurrence or comments. In the event that the Contracting Officer does not communicate concurrence or comments to the Contractor
within five (5) working days following acknowledgement of receipt of the press release advance copy, concurrence may be presumed.

 

    	 	- 18 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

PART
II - CONTRACT CLAUSES

 

SECTION I - CONTRACT CLAUSES

 

ARTICLE I.1. GENERAL CLAUSES FOR A FIXED-PRICE RESEARCH AND DEVELOPMENT SBIR
PHASE I CONTRACT

 

This
contract incorporates the following clauses by reference, with the same force and effect as if they were given in full text. Upon
request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically
as follows: FAR Clauses at: http://www.acquisition.gov/far/. HHSAR Clauses at: http://www.hhs.gov/policies/hhsar/subpart352.html.

 

		a.	FEDERAL
ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

 

	FAR	 	 	 	 
	CLAUSE
    NO.	 	DATE	 	TITLE
	52.202- 1	 	Nov 2013	 	Definitions
    (Over the Simplified Acquisition Threshold)
	52.203- 12	 	Oct 2010	 	Limitation
    on Payments to Influence Certain Federal Transactions (Over $150,000)
	52.203- 17	 	Apr 2014	 	Contractor
    Employee Whistleblower Rights and Requirements to Inform
	 	 	 	 	Employees
    of Whistleblower Rights (Over the Simplified Acquisition Threshold)
	52.203- 99	 	Feb 2015	 	Prohibition
    on Contracting with Entities That Require Certain Internal Confidentiality
    Agreements (DEVIATION)
	52.204- 10	 	Oct 2015	 	Reporting
    Executive Compensation and First-Tier Subcontract Awards ($30,000 or more)
	52.204- 13	 	Jul 2013	 	System for
    Award Management Maintenance
	52.209-6	 	Oct 2015	 	Protecting
    the Government's Interest When Subcontracting With Contractors
    Debarred, Suspended, or Proposed for Debarment (Over $35,000)
	52.215-8	 	Oct
    1997	 	Order of Precedence -
    Uniform Contract Format
	52.219-6	 	Jul 1996	 	Notice of Total Small Business Set-Aside
	52.222-3	 	Jun 2003	 	Convict Labor
	52.222-21	 	Apr 2015	 	Prohibition of Segregated Facilities
	52.222-26	 	Apr 2015	 	Equal Opportunity
	52.222-35	 	Oct 2015	 	Equal Opportunity for Veterans ($150,000
    or more)
	52.222-36	 	Jul 2014	 	Equal Opportunity for Workers with
    Disabilities
	52.222-37	 	Feb 2016	 	Employment Reports on Veterans ($150,000
    or more)
	52.222-50	 	Mar 2015	 	Combating Trafficking in Persons
	52.222-54	 	Oct 2015	 	Employment Eligibility Verification
    (Over the Simplified Acquisition Threshold)
	52.223-6	 	May 2001	 	Drug-Free Workplace
	52.223-18	 	Aug 2011	 	Encouraging Contractor Policies to
    Ban Text Messaging While Driving
	52.225-1	 	May 2014	 	Buy American - Supplies
	52.225-13	 	Jun 2008	 	Restrictions on Certain Foreign Purchases
	52.227-1	 	Dec 2007	 	Authorization and Consent, Alternate
    I (Apr 1984)
	52.227-2	 	Dec 2007	 	Notice and Assistance Regarding Patent
    and Copyright Infringement

 

    	 	- 19 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

	FAR

CLAUSE NO.
	 	DATE	 	TITLE
	52.227-11	 	May
    2014	 	Patent
    Rights - Ownership by the Contractor (Note: In accordance with FAR 27.303(b)(2), paragraph (e) is modified to include the
    requirements in FAR 27.303(b)(2)(i) through (iv). The frequency of reporting in (i) is annual.
	52.227-20	 	May 2014	 	Rights in Data
    - SBIR Program
	52.232-9	 	Apr 1984	 	Limitation on
    Withholding of Payments
	52.232-23	 	May 2014	 	Assignment of
    Claims
	52.232-25	 	Jul 2013	 	Prompt Payment
	52.232-33	 	Jul 2013	 	Payment by Electronic
    Funds Transfer—System for Award Management
	52.232-39	 	Jun 2013	 	Unenforceability
    of Unauthorized Obligations
	52.233-1	 	May 2014	 	Disputes
	52.233-3	 	Aug 1996	 	Protest After
    Award
	52.233-4	 	Oct 2004	 	Applicable Law
    for Breach of Contract Claim
	52.243-1	 	Aug 1987	 	Changes - Fixed
    Price, Alternate V (Apr 1984)
	52.244-6	 	Jun 2016	 	Subcontracts
    for Commercial Items
	52.249-1	 	Apr 1984	 	Termination
    for the Convenience of the Government (Fixed-Price) (Short Form)
	52.249-9	 	Apr 1984	 	Default (Fixed-Price
    Research and Development)(Over the Simplified Acquisition Threshold)
	52.253-1	 	Jan 1991	 	Computer Generated
    Forms

 

b. DEPARTMENT
OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR CHAPTER 3) CLAUSES:

 

	

        HHSAR
	 	 	 	 
	CLAUSE
    NO.	 	DATE	 	TITLE
	352.203-70	 	Dec
    2015	 	Anti-Lobbying
	352.222-70	 	Dec 2015	 	Contractor Cooperation in Equal Employment
    Opportunity Investigations
	352.227-70	 	Dec 2015	 	Publications and Publicity
	352.237-75	 	Dec 2015	 	Key Personnel

 

[End
of GENERAL CLAUSES FOR A FIXED-PRICE RESEARCH AND DEVELOPMENT SBIR PHASE I CONTRACT- Rev. 08/2016].

 

ARTICLE
I.2. AUTHORIZED SUBSTITUTION OF CLAUSES

 

ARTICLE
I.1. of this SECTION is hereby modified as follows:

 

		a.	Alternate
IV (October 2010) of FAR Clause 52.215-21, Requirements for Certified Cost
or Pricing Data and Data Other Than Certified Cost or Pricing Data—Modifications (October
2010) is added.

 

		b.	The
following clause(s) are added to this contract:

 

		•	FAR
                                         Clause 52.203-3, Gratuities (April 1984)

 

		•	FAR
                                         Clause 52.203-5, Covenant Against Contingent Fees (May 2014)

 

    	 	- 20 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		•	FAR
                                         Clause 52.203-6, Restrictions on Subcontractor Sales to the Government (September
                                         2006)

 

		•	FAR
                                         Clause 52.203-7, Anti-Kickback Procedures (May 2014)

 

		•	FAR
                                         Clause 52.203-8, Cancellation, Rescission, and Recovery of Funds for Illegal or Improper
                                         Activity (May 2014)

 

		•	FAR
                                         Clause 52.203-10, Price or Fee Adjustment for Illegal or Improper Activity (May
                                         2014)

 

		•	FAR
                                         Clause 52.204-4, Printed or copied Double-Sided on Postconsumer Fiber Content Paper
                                         (May 2011)

 

		•	FAR
                                         Clause 52.215-2, Audit and Records Negotiation (October 2010)

 

		•	FAR
                                         Clause 52.215-14, Integrity of Unit Prices (October 2010)

 

		•	FAR
                                         Clause 52.219-8, Utilization of Small Business Concerns (October 2014)

 

		•	FAR
                                         Clause 52.219-14, Limitations on Subcontracting (December 1996)

 

		•	FAR
                                         Clause 52.222-40, Notification of Employee Rights Under the National Labor Relations
                                         Act (December 2010)

 

		•	FAR
                                         Clause 52.229-3, Federal, State and Local Taxes (February 2013)

 

		•	FAR
                                         Clause 52.232-2, Payments under Fixed-Price Research and Development Contracts
                                         (April 1984)

 

		•	FAR
                                         Clause 52.232-17, Interest (May 2014)

 

		•	FAR
                                         Clause 52.242-13, Bankruptcy (July 1995)

 

		•	FAR
                                         Clause 52.244-5, Competition in Subcontracting (December 2010)

 

The following
clause(s) is substituted as follows:

 

		•	FAR
                                         Clause 52.249-1, Termination for the Convenience of the Government (Fixed-Price)(Short
                                         Form) (April 1984) is deleted in its entirety and FAR Clause 52.249-2, Termination
                                         for the Convenience of the Government (Fixed Price) (April 2012) is substituted therefor.

 

ARTICLE
I.3. Additional Contract Clauses

 

This
contract incorporates the following clauses by reference, with the same force and effect, as if they were given in

full
text. Upon request, the Contracting Officer will make their full text available.

 

		a.	FEDERAL
ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES

 

		1.	FAR
Clause 52.204-18 Commercial and Government Entity Code Maintenance (July 2016)

 

		2.	FAR
Clause 52.209-10, Prohibition on Contracting With Inverted Domestic Corporations (November 2015).

 

		3.	FAR
Clause 52.219-28, Post-Award Small Business Program Rerepresentation (July 2013).

 

		b.	DEPARTMENT
OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CHAPTER 3) CLAUSES:

 

		1.	HHSAR
Clause 352.208-70, Printing and Duplication (December 2015)

 

    	 	- 21 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

		2.	HHSAR
                                         Clause 352.223-70, Safety and Health (December 2015)

 

		3.	HHSAR
                                         Clause 352.231-70, Salary Rate Limitation (December 2015)

 

Note:
The Salary Rate Limitation is at the Executive Level II Rate.

 

See
the following website for Executive Schedule rates of pay:  https://www.opm.gov/policy-data-oversight/pay-leave/salaries-wages/.

 

(
For current year rates, click on Salaries and Wages/Executive Schedule/Rates of Pay for the Executive Schedule. For
prior year rates, click on Salaries and Wages/select Another Year at the top of the page/Executive Schedule/Rates of Pay for the
Executive Schedule. Rates are effective January 1 of each calendar year unless otherwise noted.)

 

ARTICLE
I.4. ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT

 

This
contract incorporates the following clauses in full text.

 

		a.	THERE
ARE NO APPLICABLE CLAUSES IN THIS SECTION.

 

    	 	- 22 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

PART
III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

 

SECTION J - LIST OF ATTACHMENTS

 

The
following documents are attached and incorporated in this contract:

 

1. Statement
of Work

 

Statement
of Work, dated September 19, 2016, 2 pages.

 

2.
Invoice Instructions for NIH Fixed-Price Contracts, NIH(RC)-2

 

Invoice
Instructions for NIH Fixed-Price Contracts, NIH(RC)-2, (8/12), 3 pages.

 

3.
Safety and Health

 

Safety
and Health, HHSAR Clause 352.223-70, (12/15), 2 pages.

 

4. Disclosure
of Lobbying Activities, SF-LLL

 

Disclosure
of Lobbying Activities, SF-LLL, dated 7/97, 2 pages.

 

5. NIH
Small Business Innovation Research (SBIR) Program Funding Agreement Certification

 

NIH
Small Business Innovative Research (SBIR) Program Funding Agreement Certification, 3 pages, located at: http://grants.nih.gov/grants/funding/sbir
_ forms/SBIR%20Funding%20Agreement%20Certification.pdf.

 

6. NIH
Small Business Innovation Research (SBIR) Program Life Cycle Certification

 

NIH
Small Business Innovative Research (SBIR) Program Life Cycle Certification, 3 pages, located at: http:// grants.nih.gov/grants/funding/sbir
_ forms/SBIR%20Life%20Cycle%20Certification.pdf.

 

    	 	- 23 -	 

    Contract Number : HHSN261201600038C
 NCI Control Number : N43CO-2016-00038

    

 

PART
IV - REPRESENTATIONS AND INSTRUCTIONS

 

SECTION K - REPRESENTATIONS AND CERTIFICATIONS

 

The
following documents are incorporated by reference in this contract:

 

		1.	FAR Clause 52.204-19
                                         Incorporation by Reference of Representations and Certifications (December 2014).

 

The Contractor's
representations and certifications, including those completed electronically via the System for Award Management (SAM), are incorporated
by reference into the contract.

 

(End of clause)

 

		5.	Animal
Welfare Assurance Number A3282-1.

 

END
of the SCHEDULE

 

(CONTRACT)

 

    	 	- 24 -	 

    Statement of Work (Phase I) Dated 09/19/2016
 Contract No. HHSN261201600038C

    

 

STATEMENT
OF WORK (Phase I)

 

	TITLE:	Cell-Based Models for Prostate Cancer Health Disparity Research
	PRINCIPAL INVESTIGATOR: 	Dr. Johng Rhim
	PROJECT DURATION:	9 months
	COMPANY:	Shuttle Pharmaceuticals, LLC
	SUBCONTRACTORS:	Georgetown University

 

		I.	Background
Information and Objectives

		A.	Background
Information

Prostate cancer
health disparities studies have shown that African-American (AA) men are at higher risk for developing prostate cancer, as well
as at higher risk of cancer specific death rates, as compared to Caucasian American (CA) men. The causes of disparities have been
attributed to socioeconomic differences, environmental exposures and biological factors. Most disparities studies have been population
based, in part, due to the lack of relevant in vitro and in vivo models to support biological studies. In this Phase I proposal,
we will develop an annotated AA prostate epithelial cancer cell line with donor matched normal prostate epithelial cells and bio-banked
reference prostate tissues. To support the feasibility of establishing 50 prostate cancer cell lines from AA men in a subsequent
Phase II application, we will prepare written protocols for tissue collection, processing, establishment of conditionally reprogrammed
cells and the reagents necessary for performing studies with these cells. We will determine commercial feasibility for cell distribution
and reagent marketing through a private-public partnership.

 

		B.	Technical
Objectives

The
three technical objectives of this proposal focus on determining the feasibility for establishing paired cancer and normal epithelial
cell lines from African-American patients presenting with prostate cancers. In the first objective, three previously harvested,
de-identified and bio-banked prostate cells from AA patients will be grown and characterized to develop standard operating protocols
and optimal media conditions. The second objective will be to optimize growth medium for use with AA cell lines. The third objective
is to negotiate intellectual property (license) through Georgetown University to support commercialization of AA cell lines.

 

Objective
1. Grow paired cancer and normal epithelial cells from AA prostate tumors and normal biopsy specimens bio-banked on IRB protocol
# 2012-163.

 

Task
1.1. Establish malignant and non-malignant cell lines from AA prostatectomy
specimens.

Milestone
1.1. Expand and freeze 20 vials for each AA cell line to perform
characterizations.

 

Task
1.2. Characterize and annotate AA cells.

Milestone
1.2. Full characterization of AA cell lines, including: cell
origin, cell growth > 30 passages, capacity to form xenograft tumors, karyotypes, expression of prostate tissue and tumor
specific markers, STR authentication and Mycoplasma testing

 

Task
1.3. Expand early passages of CRCs for freezing and banking in the
CRC bio-repository.

Milestone
1.3. 50 vials of 1 -2x10^6 cells/vial are banked for each normal/tumor
AA cell pair.

 

Task
1.4. Prepare written protocols and standard operating procedures
(SOPs) for establishing AA cell lines.

Milestone
1.4. SOPs for establishing AA cell lines and SOPs for cell growth
and annotation.

 

Objective
2. Determine the optimal growth medium and conditions for growing prostate CRCs with and without irradiated feeder cells.

 

Task
2.1. Collect and concentrate the conditioned medium from J2-irradiated
fibroblasts in sufficient quantity to support AA cell growth in 50 flasks. Test effects of graded concentrations of conditioned
medium on AA cells using telomerase and cell growth assays.

 

Milestone
2.1.1. Documentation of effects of conditioned medium on AA cell
growth.

Milestone
2.1.2. Optimal formulation of conditioned medium supplement for AA
prostate cell growth.

 

Task
2.2. Optimize the panel of supplementary growth factors for AA prostate
CRC cell growth.

Milestone
2.2. Proprietary formula of growth factors needed to promote AA CRC
culture growth.

 

    	 	Page 1 	ATTACHMENT 1

    Statement of Work (Phase I) Dated 09/19/2016
 Contract No. HHSN261201600038C

    

 

Task 2.3.
Compare cell characteristics under different media and growth conditions.

Milestone
2.3. Determine cell growth over at least 30 passages, capacity to form xenograft tumors, karyotype at early and late passages
and expression of prostate specific markers.

 

Objective
3. Negotiate a licensing agreement for commercialization of AA derived cells, submit a Phase I final report to SBIR administration
and prepare a Phase II SBIR application.

 

Task
3.1. Through the GU Office of Technology Commercialization, negotiate to obtain a licensing agreement to support
commercialization of established AA cells.

Milestone
3.1. Executed licensing agreement.

 

Task
3.2. Submit a written final Phase I report to SBIR administration.

Milestone
3.2. Phase I milestones have been reached and SBIR administration is informed of the technical and commercial feasibility
of establishing 50 model AA cell lines supporting a Phase II application in response to an appropriate NIH/SBIR RFA.

 

		II.	Services to be Performed

		A.	General Requirements

		1.	The contractor shall independently perform all work
and furnish all labor, materials, supplies, equipment, and services (except as otherwise specified in the contract).

		2.	All work will be monitored by the Government Project
Officer identified in Section G of the contract.

 

		B.	Specific Requirements

 

Phase
I Milestones and Timeline

	Objectives	 	Milestone	 	Months

        1-3
	 	Months

        4-6
	 	Months

        7-9

	Objective
    1	 	 	 	***	 	***	 	***
	 	 	Milestone 1.1.Repository of 20 frozen
    vials of each initial model AA cell line.	 	X	 	 	 	 
	 	 	Milestone 1.2. Annotation data completed
    for initial AA cell lines	 	 	 	X	 	 
	 	 	Milestone 1.3. Repository of 50 frozen
    vials of each AA cell line.	 	 	 	 	 	X
	 	 	Milestone 1.4. Written protocols,
    annotation reports and SOP's.	 	 	 	X	 	X
	Objective
    2	 	 	 	 	 	***	 	***
	 	 	Milestone 2.1. Optimal media formula
    for growing AA prostate cells.	 	 	 	X	 	 
	 	 	Milestone 2.2. Growth media supplements
    for AA prostate cells.	 	 	 	X	 	 
	 	 	Milestone 2.3. Annotation of cell
    growth, xenograft tumor formation, genetic analysis, marker expression, and cell of origin	 	 	 	 	 	X
	Objective
    3	 	 	 	 	 	 	 	***
	 	 	Milestone 3.1. Executed licensing
    agreement.	 	 	 	 	 	X
	 	 	Milestone
    3.2. Written final report of achieved Phase I milestones and application for Phase II SBIR funding	 	 	 	 	 	X

 

    	 	Page 2 	ATTACHMENT 1

     

    

 

INVOICE
INSTRUCTIONS FOR NIH FIXED-PRICE CONTRACTS. NIH(RC)-2

 

Format: Submit
payment requests on Standard Form 1034, Public Voucher for Purchases and Services Other Than Personal, or the Contractor's self-generated
form provided it contains all of the information prescribed herein. DO NOT include a cover letter with the payment request.

 

Number of Copies:
Submit payment requests in the quantity specified in the Invoice Submission Instructions in Section G of the Contract Schedule.

 

Frequency:
Submit payment requests upon delivery and acceptance of goods or services unless otherwise authorized by the Contracting Officer.

 

Currency:
All NIH contracts are expressed in United States dollars. When the Government pays in a currency other than United States
dollars, billings shall be expressed, and payment by the Government shall be made, in that other currency at amounts coincident
with actual costs incurred. Currency fluctuations may not be a basis of gain or loss to the Contractor. Notwithstanding the above,
the total of all invoices paid under this contract may not exceed the United States dollars authorized.

 

Preparation
and Itemization of the Payment Request: Prepare payment requests as follows:

 

		Note:	All information must be legible or the invoice will
be considered improper and returned to the Contractor.

 

		(a)	Designated
Billing Office Name and Address: Enter the designated billing office name and address, as identified in the Invoice Submission
Instructions in Section G of the Contract Schedule.

 

		(b)	Contractor's
Name, Address, Point of Contact, TIN, and DUNS or DUNS+4 Number: Show the Contractor's name and address exactly as they appear
in the contract. Any invoice identified as improper will be sent to this address. Also include the name, title, phone number,
and e-mail address of the Point of Contact in case of questions. If the remittance name differs from the legal business name,
both names must appear on the invoice. Provide the Contractor's Federal Taxpayer Identification Number (TIN) and Data Universal
Numbering System (DUNS) or DUNS+4 number. The DUNS number must identify the Contractor's name and address exactly as stated in
the contract, and as registered in the System for Acquisition Management (SAM) database.

 

When
an approved assignment of claims has been executed, the Contractor shall provide the same information for the assignee as is required
for the Contractor (i.e., name, address, point of contact, TIN, and DUNS number), with the remittance information clearly identified
as such.

 

		(c)	Invoice/Voucher
Number: Identify each payment request by a unique invoice number, which can only be used one time regardless of the number
of contracts or orders held by an organization. For example, if a contractor has already submitted invoice number 05 on one of
its contracts or orders, it cannot use that same invoice number on any other contract or order. Payment requests with duplicate
invoice numbers will be considered improper and returned to the contractor.

 

    	 	1 	ATTACHMENT 2

     

    

 

The
NIH does not prescribe a particular numbering format but suggests using a job or account number for each contract and order
followed by a sequential invoice number (example: 8675309-05). Invoice numbers are limited to 30 characters. There are no
restrictions on the use of special characters, such as colons, dashes, forward slashes, or parentheses.

 

If all or part
of an invoice is suspended and the contractor chooses to reclaim those costs on a supplemental invoice, the contractor may use
the same unique invoice number followed by an alpha character, such as "R" for revised (example: 8675309-05R).

 

		(d)	Date
Invoice/Voucher Prepared: Insert the date the payment request is prepared.

 

		(e)	Contract
Number and Order Number (if applicable): Insert the contract number and order number (as applicable).

 

		(f)	Contract
Title: Insert the contract title listed on the cover page of the contract and/or Section G of the Contract Schedule.

 

		(g)	Current
Contract Period of Performance: Insert the contract start date/effective date through the current completion date of the contract.

 

		(h)	Total
Fixed-Price of Contract/Order: Insert the total fixed-price of the contract/order.

 

		(i)	Two-Way/Three-Way
Match: Identify whether payment is to be made using a two-way or three-way match. To determine required payment method, refer
to the Invoice Submission Instructions in Section G of the Contract Schedule.

 

		(j)	Office of Acquisitions: Insert the name of the Office
of Acquisitions, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule.

 

		(k)	Central Point of Distribution: Identify the Central
Point of Distribution, as specified in the Invoice Submission Instructions in Section G of the Contract Schedule.

 

		(l)	Billing Period: Insert the beginning and ending
dates (month, day, and year) of the period in which costs were incurred and for which reimbursement is claimed.

 

		(m)	Description of Supplies or Services: Provide a description
of the supplies or services, by line item (if applicable), quantity, unit price (where appropriate), and total amount. The item
description, unit of measure, and unit price must match those specified in the contract. For example, if the contract specifies
1 box of hypodermic needles (100/box) with a unit price of $50.00, then the invoice must state 1 box, hypodermic needles (100/box),
$50.00, not 100 syringes at $0.50 each. Invoices that do not match the line item pricing in the contract will be considered
improper and will be returned to the Contractor.

 

		(n)	Amount Billed - Current Period: Insert the amount
claimed for the current billing period, including any adjustments, if applicable. If the Contract Schedule contains separately
priced line items, identify the contract line item(s) on the payment request.

 

		(o)	Amount Billed - Cumulative: Insert the cumulative
amounts claimed to date, including any adjustments as applicable. If the Contract Schedule contains separately priced line items,
identify the contract line item(s) on the payment request.

 

    	 	2 	ATTACHMENT 2

     

    

 

		(p)	Freight or Delivery Charges: Identify all charges
for freight or express shipments, other than f. o.b. destination, as
a separate line item on the invoice. (If shipped by freight or express, and charges are more than $25, attach prepaid bill.)

 

		(q)	Government Property: If the contract authorizes
the purchase of any item of Government Property (e.g., equipment), the invoice must list each item for which reimbursement is
requested. Include reference to the following (as applicable):

 

		-	item
number for the specific piece of equipment listed in the Property Schedule, and

		-	Contracting
Officer Authorization (COA) Number, if the equipment is not covered by the Property Schedule.

 

    	 	3 	ATTACHMENT 2

     

    

 

Safety
and Health, HHSAR 352.223-70 (DEC 2015)

 

		a.	To help ensure the protection of the life and health of
all persons, and to help prevent damage to property, the Contractor shall comply with all Federal, State, and local laws and regulations
applicable to the work being performed under this contract. These laws are implemented or enforced by the Environmental Protection
Agency, Occupational Safety and Health Administration (OSHA) and other regulatory/enforcement agencies at the Federal, State,
and local levels.

		1.	In
addition, the Contractor shall comply with the following regulations when developing and implementing health and safety operating
procedures and practices for both personnel and facilities involving the use or handling of hazardous materials and the conduct
of research, development, or test projects:

		I.	29
                                         CFR 1910.1030, Bloodborne pathogens; 29 CFR 1910.1450, Occupational exposure to hazardous
                                         chemicals in laboratories; and other applicable occupational health and safety standards
                                         issued by OSHA and included in 29 CFR part
                                         1910. These regulations are available at https://www.osha.gov/.

		II.	Nuclear
Regulatory Commission Standards and Regulations, pursuant to the Energy Reorganization Act of 1974 (42 U.S.C. 5801 et seq.). The
Contractor may obtain copies from the U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001.

 

		2.	The
following Government guidelines are recommended for developing and implementing health and safety operating procedures and practices
for both personnel and facilities:

		I.	Biosafety
in Microbiological and Biomedical Laboratories, CDC. This publication is available at http://www.cdc.gov/biosafety/publications/index.htm.

		II.	Prudent
Practices for Safety in Laboratories (1995), National Research Council, National Academy Press, 500 Fifth Street NW., Lockbox
285, Washington, DC 20055 (ISBN 0-309-05229-7). This publication is available at http://www.nap.edu/catalog/4911/prudent-practices-in-the-

laboratory-handling-and-disposal-of-chemicals.

 

		b.	Further,
the Contractor shall take or cause to be taken additional safety measures as the Contracting Officer, in conjunction with the
Contracting Officer's Representative or other appropriate officials, determines to be reasonably necessary. If compliance with
these additional safety measures results in an increase or decrease in the cost or time required for performance of any part of
work under this contract, the Contracting Officer will make an equitable adjustment in accordance with the applicable ''Changes''
clause set forth in this contract.

 

    	 	 	ATTACHMENT 3

     

    

 

		c.	The
Contractor shall maintain an accurate record of, and promptly report to the Contracting Officer, all accidents or incidents resulting
in the exposure of persons to toxic substances, hazardous materials or hazardous operations; the injury or death of any person;
or damage to property incidental to work performed under the contract resulting from toxic or hazardous materials and resulting
in any or all violations for which the Contractor has been cited by any Federal, State or local regulatory/enforcement agency.
The report citing all accidents or incidents resulting in the exposure of persons to toxic substances, hazardous materials or
hazardous operations; the injury or death of any person; or damage to property incidental to work performed under the contract
resulting from toxic or hazardous materials and resulting in any or all violations for which the Contractor has been cited shall
include a copy of the notice of violation and the findings of any inquiry or inspection, and an analysis addressing the impact
these violations may have on the work remaining to be performed. The report shall also state the required action(s), if any, to
be taken to correct any violation(s) noted by the Federal, State, or local regulatory/enforcement agency and the time frame allowed
by the agency to accomplish the necessary corrective action.

 

		d.	If
the Contractor fails or refuses to comply with the Federal, State or local regulatory/enforcement agency's directive(s) regarding
any violation(s) and prescribed corrective action(s), the Contracting Officer may issue an order stopping all or part of the work
until satisfactory corrective action (as approved by the Federal, State, or local regulatory/enforcement agencies) has been taken
and documented to the Contracting Officer. No part of the time lost due to any such stop work order shall form the basis for a
request for extension or costs or damages by the Contractor.

 

		e.	The
Contractor shall insert the substance of this clause in each subcontract involving toxic substances, hazardous materials, or hazardous
operations. The Contractor is responsible for the compliance of its subcontractors with the provisions of this clause.

 

(End of clause)

 

    	 	 	ATTACHMENT 3

     

    

 

	 	DISCLOSURE
    OF LOBBYING ACTIVITIES	Approved
    by OMB
	 	Complete this form to disclose lobbying
    activities pursuant to 31 U.S.C. 1352	0348-0046
	 	(See reverse for public burden
    disclosure.)	 

 

	1.
        Type of Federal Action:

         ̈      a. contract

        b.
        grant

        c.
        cooperative agreement

        d.
        loan

        e.
        loan guarantee

        f.
        loan insurance
	 	2.
        Status of Federal Action:

         ̈   a.
        bid/offer/application

        b.
        initial award

        c.
        post-award
	 	3.
        Report Type:

         ̈
        a. initial filing

           b.
        material change 

        

        For
        Material Change Only:

        year
        _____quarter date_____ of last report____________

	4.
        Name and Address of Reporting Entity:

         ̈ Prime     
 ̈
Subawardee

        Tier______
        , if known : 

         

         

        Congressional
        District, if known:
	 	5.
        If Reporting Entity in No. 4 is a Subawardee, Enter Name and Address of Prime:

        ______________________________________

         ______________________________________

         ______________________________________

         ______________________________________

         ______________________________________

        Congressional
        District, if known:____________

	6.
        Federal Department/Agency:

        ___________________________________
	 	7.
        Federal Program Name/Description:

         ______________________________________

         

        CFDA
        Number, if applicable :_______________

         

	8.
        Federal Action Number, if known:

        ___________________________________
	 	9.
        Award Amount, if known: 

          $  __________________

	10.
        a. Name and Address of Lobbying Registrant

        (if
        individual, last name, first name, MI):

         

        ___________________________________

         ___________________________________

         ___________________________________

         ___________________________________

        ___________________________________
	 	b.
        Individuals Performing Services (including address if different from
        No. 10a)

        (last
        name, first name, MI):

        _______________________________________

	11
    Information requested through this form is authorized by title 31 U.S.C. section 1352. This disclosure of lobbying activities
    is a material representation of fact upon which reliance was placed by the tier above when this transaction was made or entered
    into. This disclosure is required pursuant to 31 U.S.C. 1352. This information will be available for public inspection. Any
    person who fails to file the required disclosure shall be subject to a civil penalty of not less than $10,000 and not more
    than $100,000 for each such failure.	 	Signature: ____________________________________
	 	Print
    Name: ___________________________________
	 	Title: ________________________________________
	 	Telephone
No.:________________ Date: ___________

 

	Federal Use Only:	 	
        Authorized
for Local Reproduction

        Standard
        Form LLL (Rev. 7-97)

 

	PRINT	 

 

    	 	1	Attachment 4

     

    

 

INSTRUCTIONS
FOR COMPLETION OF SF-LLL, DISCLOSURE OF LOBBYING ACTIVITIES

 

This
disclosure form shall be completed by the reporting entity, whether subawardee or prime Federal recipient, at the initiation or
receipt of a covered Federal action, or a material change to a previous filing, pursuant to title 31 U.S.C. section 1352. The
filing of a form is required for each payment or agreementto make payment to any lobbying entity for influencing or attempting
to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of
a Member of Congress in connection with a covered Federal action. Complete all items that apply for both the initial filing and
material change report. Refer to the implementing guidance published by the Office of Management and Budget for additional information.

 

		1.	Identify
the type of covered Federal action for which lobbying activity is and/or has been secured to influence the outcome of a covered
Federal action.

 

		2.	Identify
the status of the covered Federal action.

 

		3.	Identify
the appropriate classification of this report. If this is a followup report caused by a material change to the information previously
reported, enter the year and quarter in which the change occurred. Enter the date of the last previously submitted report by this
reporting entity for this covered Federal action.

 

		4.	Enter
the full name, address, city, State and zip code of the reporting entity. Include Congressional District, if known. Check the
appropriate classification of the reporting entity that designates if it is, or expects to be, a prime or subaward recipient.
Identify the tier of the subawardee,e.g., the first subawardee of the prime is the 1st tier. Subawards include but are not limited
to subcontracts, subgrants and contract awards under grants.

 

		5.	If
the organization filing the report in item 4 checks "Subawardee," then enter the full name, address, city, State and
zip code of the prime Federal recipient. Include Congressional District, if known.

 

		6.	Enter
the name of the Federal agency making the award or loan commitment. Include at least one organizational level below agency name,
if known. For example, Department of Transportation, United States Coast Guard.

 

		7.	Enter
the Federal program name or description for the covered Federal action (item 1). If known, enter the full Catalog of Federal Domestic
Assistance (CFDA) number for grants, cooperative agreements, loans, and loan commitments.

 

		8.	Enter
the most appropriate Federal identifying number available for the Federal action identified in item 1 (e.g., Request for Proposal
(RFP) number; Invitation for Bid (IFB) number; grant announcement number; the contract, grant, or loan award number; the application/proposal
control number assigned by the Federal agency). Include prefixes, e.g., "RFP-DE-90-001."

 

		9.	For
a covered Federal action where there has been an award or loan commitment by the Federal agency, enter the Federal amount of the
award/loan commitment for the prime entity identified in item 4 or 5.

 

	10.	(a)	Enter the full name, address, city, State and zip code of the lobbying registrant under the Lobbying Disclosure Act of 1995 engaged
by the reporting entity identified in item 4 to influence the covered Federal action.

 

		(b)	Enter the full names of the individual(s) performing
services, and include full address if different from 10 (a). Enter Last Name, First Name, and Middle Initial (MI).

 

		11.	The
certifying official shall sign and date the form, print his/her name, title, and telephone number.

 

	According to the Paperwork Reduction Act, as amended, no persons are required to respond to a collection of information unless it displays a valid OMB Control Number. The valid OMB control number for this information collection is OMB No. 0348-0046. Public reporting burden for this collection of information is estimated to average 10 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction Project (0348-0046), Washington, DC 20503.

 

    	 	2	Attachment 4

     

    

 

SBIR
Funding Agreement Certification

 

	Grant Contract Number:	 

 

	Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)):	 

 

Public reporting burden for this collection of information is
estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering
and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor,
and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for
reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0001).
Do not return the completed form to this address.

 

All small businesses that are selected for award of an SBIR
funding agreement must complete this certification at the time of award and any other time set forth in the Notice of Award or
Contract Award that is prior to performance of work under this award. This includes checking all of the boxes and having an authorized
officer of the awardee sign and date the certification each time it is requested.

 

Please read carefully the following certification statements.
The Federal government relies on this information to determine whether the business is eligible for a Small Business Innovation
Research (SBIR) Program award. A similar certification will be used to ensure continued compliance with specific program requirements
during the life of the funding agreement. The definitions for the terms used in this certification are set forth in the Small Business
Act, SBA regulations (13 C.F.R. Part 121), the SBIR Policy Directive and also any statutory and regulatory provisions references
in those authorities.

 

If the Grants Management or Contracting Officer believes that
the business may not meet certain eligibility requirements at the time of award, they are required to file a size protest with
the U.S. Small Business Administration (SBA), who will determine eligibility. At that time, SBA will request further clarification
and supporting documentation in order to assist in the verification of any of the information provided as part of a protest. If
the Grants Management or Contracting Officer believes, after award, that the business is not meeting certain Notice of Award requirements,
the agency may request further clarification and supporting documentation in order to assist in the verification of any of the
information provided.

 

Even if correct information has been included in other materials
submitted to the Federal government, any action taken with respect to this certification does not affect the Government’s
right to pursue criminal, civil, or administrative remedies for incorrect or incomplete information given in the certification.
Each person signing this certification may be prosecuted if they have provided false information.

 

The undersigned has reviewed, verified and certifies that (all
boxes must be checked):

 

		1.	The business concern meets the ownership and control
requirements set forth in 13 C.F.R. § 121.702.

 

 ̈ Yes
 ̈ No

 

		2.	If a corporation, all corporate documents (articles of incorporation and any amendments, articles of conversion, by-laws and
amendments, shareholder meeting minutes showing director elections, shareholder meeting minutes showing officer elections, organizational
meeting minutes, all issued stock certificates, stock ledger, buy-sell agreements, stock transfer agreements, voting agreements,
and documents relating to stock options, including the right to convert non-voting stock or debentures into voting stock) evidence
that it meets the ownership and control requirements set forth in 13 C.F.R. § 121.702.

 

	 ̈ Yes  ̈ No  ̈ N/A	Explain why N/A:	 

 

		3.	If a partnership, the partnership agreement evidences that it meets the ownership and control requirements set forth in 13
C.F.R. § 121.702.

 

	 ̈ Yes  ̈ No  ̈ N/A	Explain why N/A:	 

 

		4.	If a limited liability company, the articles of organization and any amendments, and operating agreements and amendments, evidence
that it meets the ownership and control requirements set forth in 13 C.F.R. § 121.702.

 

	 ̈ Yes  ̈ No  ̈ N/A	Explain why N/A:	 

 

    	 	1	Attachment 5

     

    

 

		5.	The birth certificates, naturalization papers, or passports show that any individuals it relies upon to meet the eligibility
requirements are U.S. citizens or permanent resident aliens in the United States.

 

	 ̈ Yes  ̈ No  ̈ N/A	Explain why N/A:	 

 

		6.	It has no more than 500 employees, including the employees
of its affiliates.

 

 ̈ Yes
 ̈ No

 

		7.	SBA has not issued a size determination currently in effect finding that this business concern exceeds the 500 employee size
standard.

 

 ̈ Yes
 ̈ No

 

		8.	During the performance of the award, the principal investigator will spend more than half of his/her time as an employee of
the awardee or has requested and received a written deviation from this requirement from the Grants Management or Contracting Officer.

 

 ̈ Yes
 ̈ No Deviation
approved in writing by Grants Management or Contracting Officer:      %

 

		9.	All, essentially equivalent work, or a portion of the work proposed under this project (check the applicable line):

 

 ̈ Has
not been submitted for funding by another Federal agency

 ̈ Has
been submitted for funding by another Federal agency but has not been funded under any other Federal grant, contract, subcontract,
or other transaction.

 ̈ A
portion has been funded by another grant, contract, or subcontract as described in detail in the proposal and approved
in writing by the Grants Management or Contracting Officer.

 

		10.	During the performance of award, it will perform the applicable percentage of work unless a deviation from this requirement
is approved in writing by the Grants Management or Contracting Officer (check the applicable line and fill in if needed):

 

 ̈ SBIR
Phase I: at least two-thirds (66 2/3%) of the research

 ̈ SBIR
Phase II: at least half (50%) of the research

 ̈ Deviation
approved in writing by the Grants Management or Contracting Officer:            %

 

		11.	During performance of award, the research/research and development will be performed in the United States unless a deviation
is approved in writing by the Grants Management or Contracting Officer.

 

 ̈ Yes
 ̈ No

 

		12.	During the performance of award, the research/research and development will be performed at my facilities with my employees,
except as otherwise indicated in the SBIR application and approved in the Notice of Award or Contract Award.

 

 ̈ Yes
 ̈ No

 

		13.	It has registered itself on SBA’s database as majority-owned by venture capital operating companies, hedge funds or private
equity firms.

 

	 ̈ Yes
     ̈
    No  ̈
    N/A 	Explain why N/A:	 

 

		14.	It is a Covered Small Business Concern (a small business concern that: (a) was not majority-owned by multiple venture capital
operating companies (VCOCs), hedge funds, or private equity firms on the data on which it submitted an application in response
to an SBIR solicitation; and (b) on the date of the SBIR award, which is made more than 9 months after the closing date of the
solicitation, is majority-owned by multiple venture capital operating companies, hedge funds, or private equity firms).

 

 ̈ Yes
 ̈ No

 

    	 	2	SBIR Funding Agreement
Attachment 5
Certification

     

    

 

		15.	It will notify the Federal agency immediately if all or a portion of the work proposed is subsequently funded by another Federal
agency.

 

 ̈ Yes
 ̈ No

 

I understand that the information submitted may be given to
Federal, State and local agencies for determining violations of law and other purposes.

 

I am an officer of the business concern authorized to represent
it and sign this certification on its behalf. By signing this certification, I am representing on my own behalf, and on behalf
of the business concern that the information provided in this certification, the application, and all other information submitted
in connection with this application, is true and correct as of the date of submission. I acknowledge that any intentional or negligent
misrepresentation of the information contained in this certification may result in criminal, civil or administrative sanctions,
including but not limited to: (1) fines, restitution and/or imprisonment under 18 U.S.C. § 1001; (2) treble damages and civil
penalties under the False Claims Act (31 U.S.C. § 3729 et seq); (3) double damages and civil penalties under the Program Fraud
Civil Remedies Act (31 U.S.C. §3801 et seq); (4) civil recovery of award funds; (5) suspension and/or debarment from all Federal
procurement and nonprocurement transactions (FAR Subpart 9.4 or 2 C.F.R. part 180; and (6) other administrative penalties including
termination of SBIR/STTR awards.

 

	Date	 

 

	Signature	 

 

	Printed Name (First, Middle, Last)	 

 

	Title	 

 

	Organization Name	 

 

    	 	3	SBIR Funding Agreement
Attachment 5
Certification

     

    

 

HHS Small
Business Innovation Research Program Life Cycle Certification

 

Public reporting burden for this collection
of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing
data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency
may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently
valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD
20892-7974, ATTN: PRA (0925-0001). Do not return the completed form to this address.

 

All SBIR Phase I and Phase II awardees must complete this certification
at all times set forth in the funding agreement (see §8(h) of the SBIR Policy Directive). This includes checking all of the
boxes and having an authorized officer of the awardee sign and date the certification each time it is required. Awardees are not
required to submit this certification directly to NIH but must instead complete the certification and maintain it on file in accordance
with the records and retention policy in Section 8.4.2 of the NIH Grants Policy Statement or as listed in the SBIR contract solicitation
or contract award.

 

A certification is required at the following
times:

 

		•	For SBIR Phase I Awardees: At the time of receiving final payment or disbursement from the Payment Management System or via
contract.

 

		•	For SBIR Phase II Awardees: prior to receiving more than 50% of the total award amount and prior to final payment or disbursement
from the Payment Management System or via contract.

 

In addition, SBIR awardees indicate compliance with these certification
requirements by drawing or requesting funds from the Payment Management System. If the grantee cannot complete this certification
or cannot ensure compliance with the certification process, it should notify the funding agreement officer immediately. If resolution
cannot be reached, the funding agreement officer will void or terminate the award, as appropriate.

 

	Grant or Contract Number:	 

 

	Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)):	 

 

Please read carefully the following certification statements.
The Federal government relies on the information to ensure compliance with specific program requirements during the life of the
funding agreement. The definitions for the terms used in this certification are set forth in the Small Business Act, the SBIR Policy
Directive, and also any statutory and regulatory provisions referenced in those authorities.

 

If the funding agreement officer believes that the business
is not meeting certain funding agreement requirements, the agency may request further clarification and supporting documentation
in order to assist in the verification of any of the information provided.

 

Even if correct information has been included in other materials
submitted to the Federal government, any action taken with respect to this certification does not affect the Government’s
right to pursue criminal, civil or administrative remedies for incorrect or incomplete information given in the certification.
Each person signing this certification may be prosecuted if they have provided false information.

 

    	 	1	SBIR Life Cycle Certification
Attachment 6

     

    

 

The undersigned has reviewed, verified
and certifies that (all boxes must be checked):

 

		1.	The principal investigator spent more than one half of his/her time as an employee of the awardee or has requested and received
a written deviation from this requirement from the funding agreement officer.

 

 ̈ Yes
 ̈ No Deviation
approved in writing by funding agreement officer:       %

 

		2.	All, essentially equivalent work, or a portion of the work performed under this project (check
the applicable line):

 

 ̈ Has
not been submitted for funding by another Federal agency.

 ̈
Has been submitted for funding by another Federal agency but has not been funded under any other Federal grant, contract, subcontract,
or other transaction.

 ̈ A
portion has been funded by another grant, contract, or subcontract as described in detail in the proposal and approved in writing
by the funding agreement officer.

 

		3.	Upon completion of the award it will have performed the applicable percentage of work, unless a
deviation from this requirement is approved in writing by the funding agreement officer (check the applicable line and fill in
if needed):

 

 ̈ SBIR
Phase I: at least two-thirds (66 2/3%) of the research

 ̈ SBIR
Phase II: at least half (50%) of the research 

 ̈ Deviation
approved in writing by the funding agreement officer:       %

 

		4.	The work is completed and it has performed the applicable percentage of work, unless a deviation
from this requirement is approved in writing by the funding agreement officer (check the applicable line and fill in if needed).

 

 ̈ SBIR
Phase I: at least two-thirds (66 2/3%) of the research 

 ̈ SBIR
Phase II: at least half (50%) of the research 

 ̈ Deviation
approved in writing by the funding agreement officer:       % 

 ̈ N/A
because work is not completed

 

		5.	The research/research and development is performed in the United States unless a deviation is approved in writing by the funding
agreement officer.

 

 ̈ Yes
 ̈ No  ̈ Waiver has been granted

 

		6.	The research/research and development is performed at my facilities with my employees, except as otherwise indicated in the
SBIR application and approved in the Notice of Award or Contract Award.

 

 ̈ Yes
 ̈ No

 

 ̈ I
will notify the Federal agency immediately if all or a portion of the work proposed is subsequently funded by another Federal agency.

 

 ̈ I
understand that the information submitted may be given to Federal, State and local agencies for determining violations of law and
other purposes.

 

    	 	2	SBIR Life Cycle Certification
Attachment 6

     

    

 

 ̈ I
am an officer of the business concern authorized to represent it and sign this certification on its behalf. By signing this
certification, I am representing on my own behalf, and on behalf of the business concern that the information provided in
this certification, the application, and all other information submitted in connection with the award, is true and correct as
of the date of submission. I acknowledge that any intentional or negligent misrepresentation of the information contained in
this certification may result in criminal, civil or administrative sanctions, including but not limited to: (1) fines,
restitution and/or imprisonment under 18 U.S.C. § 1001; (2) treble damages and
civil penalties under the False Claims Act (31 U.S.. § 3729 EC Esq.); (3) double damages and civil penalties under the
Program Fraud Civil Remedies Act (31 U.S.C. §3801 et seq.); (4) civil recovery of award funds; (5) suspension and/or
debarment from all Federal procurement and nonprocurement transactions (FAR Subpart 9.4 or 2 C.F.R. part 180); and (6) other
administrative penalties including termination of SBIR/STTR awards.

 

	Date	 

 

	Signature	 

 

	Printed Name (First, Middle, Last)	 

 

	Title	 

 

	Business Name	 

 

    	 	3	
Attachment 6Exhibit 10.10

 

Non-Federal

 

Subaward Agreement

 

	Prime Awardee	Subawardee
	Institution/Organization ("PRIME RECIPIENT")	Institution/Organization ("SUBRECIPIENT")
	 	 	 	 
	Name:	Shuttle Pharmaceutical, LLC	Name:	Rhode Island Hospital
	 	 	 	 
	Address:	1 Research Court, Suite 450	Address:	593 Eddy Street
	 	Rockville, MD 20850	 	Providence, RI 02903
	 	 	 	 
	Prime Award No.

                                                 
	Subaward No.
	 	HHSN261201400013C	 	 
	 	 	 	 
	Sponsor	  

                                     
	 	 
	 	National Cancer Institute	 	 

 

	Subaward Period of Performance	Amount Funded this Action 	Est. Total (if incrementally funded)
	 	 	 	 
	Phase I 10/27/14 - 6/18/15 Phase II 6/19/15 - 6/18/17	$65,549	$688,818
	 	 	 	 
	Project Title	 	 
	 	 	 	 
	 	Development of Radiation Modulators for Use During Radiotherapy
	Reporting Requirements [Check here if applicable: x
    See Attachment 4]

 

Terms and Conditions

 

1) Prime Recipient hereby awards a cost reimbursable
subaward, as described above, to Subrecipient. The statement of work and budget for this subaward are (check one): ___ as
specified in Subrecipient’s proposal
dated                       ;
or _X_ as shown in Attachments 3 & 4. In its performance of subaward work, Subrecipient shall be an
independent entity and not an employee or agent of Prime Recipient.

2) Prime Recipient shall reimburse Subrecipient not more often than
monthly for allowable costs. All invoices shall be submitted using Subrecipient’s standard invoice, but at a minimum shall
include current and cumulative costs (including cost sharing), subaward number, and certification as to truth and accuracy of invoice.
Invoices that do not reference Prime Recipient’s subaward number shall be returned to Subrecipient. Invoices and questions
concerning invoice receipt or payments should be directed to the appropriate party’s Financial Contact, as shown in Attachment
2.

3) A final statement of cumulative costs incurred, including cost
sharing, marked “FINAL,” must be submitted to Prime Recipient’s Administrative Contact NOT LATER THAN sixty (60)
days after subaward end date. The final statement of costs shall constitute Subrecipient’s final financial report.

4) All payments shall be considered provisional and subject to adjustment
within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient.

5) Matters concerning the technical performance
of this subaward should be directed to the appropriate party’s Project Director, as shown in Attachment 2. Technical
reports are required as shown above, “Reporting Requirements.”

6) Matters concerning the request or negotiation of any changes
in the terms, conditions, or amounts cited in this subaward agreement should be directed to the appropriate party’s Administrative
Contact, as shown in Attachment 2. Any such changes made to this subaward agreement require the written approval of each
party’s Authorized Official, as shown in Attachment 2.

7) Each party shall be responsible for its
negligent acts or omissions and the negligent acts or omissions of its employees, officers or directors, to the extent allowed
by law.

8) Either party may terminate this agreement with thirty days written
notice to the appropriate party’s Administrative Contact, as shown in Attachment 2. Prime Recipient shall pay Subrecipient
for all allowable, noncancellable obligations in the event of termination.

9) No-cost extensions require the approval of the Prime Recipient.
Any requests for a no-cost extension should be addressed to and received by the Administrative Contact, as shown in Attachment
2, not less than thirty days prior to the desired effective date of the requested change.

10) The Subaward is subject to the terms and
conditions of the Prime Award and other special terms and conditions, as identified in Attachment 1.

 

	By an Authorized Official of PRIME RECIPIENT:	 	By an Authorized Official of SUBRECIPIENT:
	 	 	 	 	 	 	 
	/s/ Anatoly Dritschilo	 	10/22/2014	 		 	10/28/2014
	 	 	 	 	 	 	 
	Anatoly Dritschilo, MD - CEO	 	Date	 	 	 	Date

 

Lifespan 3/15/10

 

     

     

    

 

Non-Federal

 

	Attachment 2
	Subaward Agreement

 

	Prime Recipient Contacts	Subrecipient Contacts
	Administrative Contact	Administrative Contact
	 	 
	Name:	
        Peter D. Dritschilo

        President & CFO
	Name:	Kim-Marie Lawrence
	 	 	 	 
	Address:	
        Shuttle Pharmaceuticals, LLC

        One Research Court, Suite 450

        Rockville, MD 20850-6252
	Address:	
        Office of Research Administration

        1 Hoppin Street, Suite 1,300

        Providence, RI 02903-4141

	 	 	 	 
	Telephone:	240-271-0642	Telephone:	401.444.8554
	Fax:	301-519-8081	Fax:	401.444.4061
	Email:	hoya92@aol.com	Email:	klawrence@lifespan.org
	 	 
	Principal Investigator	Project Director
	 	 
	Name:	Theodore Phillips, MD	Name:	
        Timothy Kinsella, MD

        “Essential to the project.”

	 	 	 	 
	Address:	
        Shuttle Pharmaceuticals, LLC

        One Research Court, Suite 450

        Rockville, MD 20850-6252
	Address:	
        Rhode Island Hospital

        593 Eddy Street, APC 1

        Providence, RI 02903

	 	 	 	 
	Telephone:	240-403-4212	Telephone:	401.444.6203
	Fax:	301-519-8081	Fax:	401.444.5335
	Email:	farfa12@aol.com	Email:	tkinsella@lifespan.org
	 	 	 	 
	Financial Contact	Financial Contact
	 	 
	Name:	
        Peter D. Dritschilo President & CFO

        President & CFO
	Name:	
        Donald Hook

        Manager, Research Finance

	 	 	 	 
	Address:	
        Shuttle Pharmaceuticals, LLC

        One Research Court, Suite 450

        Rockville, MD 20850-6252
	Address:	
        Rhode Island Hospital

        1 Hoppin Street, Suite 1.300

        Providence, RI 02903-4141

	 	 	 	 
	Telephone:	240-271-0642	Telephone:	401-444-5112
	Fax:	301-519-8081	Fax:	401-444-4061
	Email:	hoya92@aol.com	Email:	dhook@lifespan.org
	 	 
	Authorized Official	Authorized Official
	 	 
	Name:	Anatoly Dritschilo, MD CEO	Name:	Joan M. Silva
	 	 	 	 
	Address:	Shuttle Pharmaceuticals, LLC 

One Research Court, Suite 450 

Rockville, MD 20850-6252	Address:	
        Administrative Manager

        Rhode Island Hospital

        Office of Research Administration

        1 Hoppin Street, Suite 1.300

        Providence, RI 02903-4141

	 	 	 	 
	Telephone:	202-444-4068	Telephone:	401.444.4006
	Fax:	301-519-8081	Fax:	401.444.4061
	Email:	dritscha@georgetown.edu	Email:	jsilva@lifespan.org

 

Lifespan 3/15/10

 

     

     

    

 

Proposed Budget - Attachment 3 

 

701
xxxx

 

IPdR (BrUOG 265)

 

	Tim Kinsella, MD	 	Start	 	 	10/22/14	 	 	 	 	 	6/19/15	 	 	 	 	 	6/19/16	 	 	 	 
	 	 	End	 	 	6/18/15	 	 	 	 	 	6/18/16	 	 	 	 	 	6/18/17	 	 	 	 
	Personnel	 	Salary	 	 	Cal Mos.	 	 	Effort	 	 	Yr 1	 	 	Cal Mos.	 	 	Effort	 	 	Yr 2	 	 	Cal Mos.	 	 	Effort	 	 	

                                                                                 Yr 3
	 	 	TOTAL	 
	Tim Kinsella, MD	 	$	181,500	 	 	 	1.45	 	 	 	12.1	%	 	$	16,448	 	 	 	2.76	 	 	 	23	%	 	$	41,745	 	 	 	2.76	 	 	 	23	%	 	$	41,557	 	 	$	99,750	 
	Howard Safran, MD	 	$	181,500	 	 	 	0.47	 	 	 	3.9	%	 	$	5,332	 	 	 	1.08	 	 	 	9	%	 	$	16,335	 	 	 	1.08	 	 	 	9	%	 	$	16,335	 	 	$	38,002	 
	Andrea Monckeberg,	 	$	125,000	 	 	 	 	 	 	 	0.0	%	 	$	0	 	 	 	0.36	 	 	 	3	%	 	$	3,825	 	 	 	0.36	 	 	 	3	%	 	$	3,902	 	 	$	7,727	 
	Mark LeGolvan, MD	 	$	181,500	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	0.00	 	 	 	0	%	 	 	 	 	 	 	0.23	 	 	 	2	%	 	$	3,479	 	 	$	3,479	 
	TBN, CRA	 	 	$53 500	 	 	 	1 70	 	 	 	14.2	%	 	$	5,684	 	 	 	1.70	 	 	 	14.2	%	 	$	5,798	 	 	 	1.70	 	 	 	14.2	%	 	$	5,914	 	 	 	$17 396	 
	TBN, Res Nurse	 	$	87,210	 	 	 	 	 	 	 	0.0	%	 	$	0	 	 	 	6.60	 	 	 	55	%	 	$	47,966	 	 	 	6.60	 	 	 	55	%	 	$	48,925	 	 	$	96,890	 
	Total Salaries	 	 	 	 	 	 	 	 	 	 	 	 	 	$	27,464	 	 	 	 	 	 	 	 	 	 	$	115,669	 	 	 	 	 	 	 	 	 	 	$	120,111	 	 	$	263,244	 
	Fringe:	 	 	 	 	 	 	 	 	 	 	31.9	%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Tim Kinsella, MD	 	 	 	 	 	 	 	 	 	 	 	 	 	$	5,247	 	 	 	 	 	 	 	 	 	 	$	13,317	 	 	 	 	 	 	 	 	 	 	$	13,257	 	 	$	31,820	 
	Howard Safran, MD	 	 	 	 	 	 	 	 	 	 	 	 	 	$	1,701	 	 	 	 	 	 	 	 	 	 	$	5,211	 	 	 	 	 	 	 	 	 	 	$	5,211	 	 	$	12,122	 
	Andrea Monckeberg,	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	1,220	 	 	 	 	 	 	 	 	 	 	$	1,245	 	 	$	2,465	 
	Mark LeGolvan, MD	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	1,110	 	 	$	1,110	 
	TBN, CRA	 	 	 	 	 	 	 	 	 	 	 	 	 	$	1,813	 	 	 	 	 	 	 	 	 	 	$	1,850	 	 	 	 	 	 	 	 	 	 	$	1,887	 	 	$	5,549	 
	TBN, Res Nurse	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	15,301	 	 	 	 	 	 	 	 	 	 	$	15,607	 	 	$	30,908	 
	Total Fringe Benefits	 	 	 	 	 	 	 	 	 	 	 	 	 	$	8,761	 	 	 	 	 	 	 	 	 	 	$	36,898	 	 	 	 	 	 	 	 	 	 	$	38,315	 	 	$	83,975	 
	Total Sal + Fringe	 	 	 	 	 	 	 	 	 	 	 	 	 	$	36,226	 	 	 	 	 	 	 	 	 	 	$	152,567	 	 	 	 	 	 	 	 	 	 	$	158,427	 	 	$	347,219	 
	Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	$	0	 
	Supplies	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Animal	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	$	0	 
	Lab Supplies	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	$	0	 
	Total Supplies	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	$	0	 
	Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	$	0	 
	Other	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Publications	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	$	0	 
	BrUOG	 	 	 	 	 	 	 	 	 	 	 	 	 	$	5,000	 	 	 	 	 	 	 	 	 	 	$	37,500	 	 	 	 	 	 	 	 	 	 	$	37,500	 	 	$	80,000	 
	Biopsy costs/ processing	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	6,000	 	 	$	6,000	 
	Total Other	 	 	 	 	 	 	 	 	 	 	 	 	 	$	5,000	 	 	 	 	 	 	 	 	 	 	$	37,500	 	 	 	 	 	 	 	 	 	 	$	43,500	 	 	$	86,000	 
	Total Direct	 	 	 	 	 	 	 	 	 	 	 	 	 	$	41,226	 	 	 	 	 	 	 	 	 	 	$	190,067	 	 	 	 	 	 	 	 	 	 	$	201,927	 	 	$	433,219	 
	Less: Equipment	 	 	 	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	 	 	 	 	 	 	 	 	$	0	 	 	$	0	 
	MTDC Indirect Base x Indirect Rate (59% as
    of 10/01/11)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$41,226
 59%
	 	 	 	 	 	 	 	 	 	 	 	$190,067
 59%
	 	 	 	 	 	 	 	 	 	 	 	$201,927
 59%
	 	 	 	$433,219
 59%
	 
	Indirect Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	24,323	 	 	 	 	 	 	 	 	 	 	$	112,139	 	 	 	 	 	 	 	 	 	 	$	119,137	 	 	$	255,599	 
	Total Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	$	65,549	 	 	 	 	 	 	 	 	 	 	$	302,206	 	 	 	 	 	 	 	 	 	 	$	321,063	 	 	$	688,818	 

 

     

     

    

  

ATTACHMENT 4 

SUBAWARD AGREEMENT

 

This attachment provides a (1) a statement
of flowdown clauses from the prime contract # HHSN261201400013C, (2) precedence of the prime contract (3)statement of work and
(4) reporting requirements for Phase I and Phase II.

 

Flowdown Clauses

 

Line 10 of the subaward agreement states "The
Subaward is subject to the terms and conditions of the Prime Award and other special terms and conditions, as identified in Attachment
1.” The Items are in sections H and I of the contract # HHSN261201400013, included in Attachment 1.

 

Order of Precedence

 

This Contract, together with the enumerated
Attachments (1-4) hereto (all of which are incorporated herein by this reference) shall comprise this Contract and shall together
be referred to as the "Sub-contract Documents.” In the event of any inconsistencies between this Contract and the Prime
Contract HHSN2612014800013C, as included in Attachment 1, the prime contract will have precedence in the interpretation or resolution
of such conflict.

 

Statement of Work - Subcontract

 

I. Background Information and Objectives

 

For NIH review of the Lifespan/RIH subcontract
and the subcontract statement of work the following summary is provided. The subcontractor will work with the PI and the prime
contractor to accomplish the following tasks. The full SOW is included in the signed contract # HHSN261201400013C.

 

PHASE I SBIR

 

A. Technical Objectives

 

Objective 1. Activate the IPdR IND for the
Phase I and PK clinical trial.

 

Task 1.1. File administrative documents
to initially cross-file (IND 70,333) and obtain an IND for the IPdR and RT clinical trial.

Milestone 1.1. An IPdR IND.

 

Task 1.2. Negotiate with CTEP to transfer
sufficient clinical product IPdR for performance of the clinical trial.

Milestone 1.2. Clinical product (encapsulated) IPdR, will
be made available for the proposed Phase I and PK clinical trial at Lifespan/RIH.

 

Lifespan

 

     

     

    

 

Objective 2. Obtain approvals for the Phase I and PK clinical
protocol. Develop efficacy protocols satisfying FDA “Orphan Drug” status.

 

Task 2.1. Submit a Letter of Intent (LOI) to NCI CTEP for
the Phase I and PK clinical studies of IPdR.

Milestone 2.1. LOI approval.

Task 2.2. Submit to the IRB the Phase I and PK study protocol.

Milestone 2.2. IRB approval of the Phase I study for IPdR
+ RT.

Task 2.3. Consult with the FDA regarding "Orphan Drug”
status for IPdR

Milestone 2.3. FDA guidance on "Orphan Drug” status for IPdR for rectal cancer.

 

Objective 3. Establish the in-house (Shuttle Pharmaceuticals.
LLC Laboratories) biomarker assays.

 

Task 3.1 will be performed at NIH and Shuttle Pharmaceuticals

Task 3.2. Prepare a written report of Phase I SBIR achievements
to NIH.

Milestone 3.2.NIH accepts the report and exercises the option
for Phase II.

 

Gantt Chart 1: Phase I. Milestones, Deliverables, Timeline
& Work Distribution. between Shuttle Pharmaceuticals, LLC (SP) and Lifespan/Rhode Island Hospital (L/RIH).

 

	 	 	 	Months
	Site	 	Milestones
    and Deliverables	 	1	 	2	 	3	 	4	 	5	 	6	 	7	 	8	 	9
	SP,	 	Objective 1. Task 1.1.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	L/RIH	 	Milestone 1.1. Activation of the IPdR IND	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 1. Task 1.2.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 1.2. IPdR clinical product for use in the Phase I clinical trial	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 1. Task 1.3.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 1.3. Capsules of IPdR for Phase I.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP,	 	Objective 2. Task 2.1.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	L/RIH	 	Milestone 2.1. CTEP approval of the Phase I and PK LOI.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP,	 	Objective 2. Task 2.2.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	L/RIH	 	Milestone 5. IRB approval of the Phase I clinical trial.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 2. Task 2.3.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 6. FDA advice regarding "Orphan Drug” status for IPdR in rectal cancer treatment.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 3. Task 3.1.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 3.1. The GLP %IUdR-DNA cellular incorporation assays established in SP laboratories.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 3. Task 3.2.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 3.2. NIH approves final report and exercises the Phase II option.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

Lifespan

 

     

     

    

 

PHASE II SBIR

 

A. Technical Objectives

 

Objective 1: Perform the Phase I and PK clinical trial of
IPdR-mediated radiosensitization.

 

Task 1.1. Perform the Phase I clinical
trial.

Milestone 1.1. Collect clinical data.

Milestone 1.3. Collect and transfer
clinical samples to SP Laboratories for analysis.

 

Objective 2: Perform PK analyses to determine
optimal dosing schedule.

 

Task 2.1. Determine
pharmacokinetics (PK) and %IUdR-DNA for biomarker analysis. 

Milestone 2.1. Clinical specimens are obtained and
analyzed for PK & % IUdR-DNA.

Milestone 2.2. PK analyses results.

Milestone 2.3. %IUdR-DNA incorporation
results and clinical correlation.

 

Objective 3: Use Phase I and PK results
to design the Phase IB/II clinical trial.

 

Task 3.1. Analyze the PK data to determine
optimal IPdR dosing.

Milestone 3.1. Optimum dosing schedule
of IPdR is established.

Task 3.2. Design and write the Phase IB/II protocol for efficacy
determination.

Milestone 3.2. Phase IB/II clinical protocol for IPdR and RT in rectal cancer.

 

Objective 4: Advance the business development and commercialization
plan.

 

Task 4.1. Use Phase I clinical trial
results to raise capital for efficacy clinical trials. 

Milestone 4.1. Written business development and commercialization.

Task 4.2. Prepare a final written report
for the Government Project Officer.

Milestone 4.1. Written final progress
report is accepted.

 

Gantt Chart 2: Phase II Milestones, Deliverables
and Work Distribution.

 

	 	 	 	 	Delivery Schedule (months)
	Site	 	Milestones and Deliverables	 	2	 	4	 	6	 	8	 	10	 	12	 	14	 	16	 	18	 	20	 	22	 	24
	L/RIH	 	Objective 1. Task 1.1 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 1.1. Initiation and performance of the Phase I and PK clinical trial of IUdR with RT. Milestone 1.2. Safety and MTD parameters for IPdR with RT. Milestone 1.3. Collect and transfer clinical samples to SP Labs.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	L/RIH	 	Objective 2. Task 2.1.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Milestone 2.1. Obtain clinical specimens for PK & %IUdR-DNA Milestone 2.2. PK analyses Milestone 2.3. %IUdR-DNA incorporation is determined and correlated with clinical observations.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 3: Task 3.1.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 3.1. Dosing schedule of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	IPdR is established, based on PK	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 3: Task 3.2.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 3.2. Written Phase IB/II clinical protocol	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP	 	Objective 4: Task 4.1.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 4.1 Written business and commercialization plan.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SP,	 	Objective 4: Task 4.2. 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	L/RIH	 	Milestone 4.2. Final report submitted to NIH.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

Shuttle Pharmaceuticals, LLC (SP); Lifespan/Rhode Island Hospital
(L/RIH)

 

Lifespan

 

     

     

    

  

Reporting Requirements

 

	Phase  I	 
	1.	Kick-off presentation 10/16/14	 
	2.	Phase I, two quarterly reports	12/19/14 and 3/19/15
	3.	Draft Updated Commercialization Plan	5/18/15
	4.	Draft Final Report and Draft Summary of Salient Results	6/18/15
	5.	Final Commercialization Plan	6/18/15
	6.	Final Report	6/18/15
	7.	Final Presentation	6/18/15

 

Phase II contract activities and reporting will be contingent on
the Government’s decision to exercise the option per Article B.# of the contract # HHSN261201400013C.

 

	Phase II	 
	1.	Option exercised	(approximately) 6/19/15
	2.	Phase II, quarterly reports exercises	every 90 days after option
	3.	Draft Final Report for Phase II and Summary of Salient Clinical Trial Results	5/19/17
	4.	Draft Phase II Final Report	6/19/17
	5.	Phase II Final Report and Presentation	6/19/17
	6.	Summary of Salient Clinical Trial Results	6/19/17

 

	Additional Reporting and Certifications	 
	 	 	 
	7.	Annual technical progress report for Clinical Research Study Populations	6/19/17
	8.	Protection of Human Subjects	6/19/15
	9.	Annual Utilization	6/19/16
	10.	Final Invention Statement and Disclosure	6/19/17
	11.	Annual Report	6/19/16
	12.	Conformance Certification	6/19/15
	13.	Financial Conflict of Interest	as it arises
	14.	Life Cycle Phase I	6/18/15
	15.	Life Cycle Phase II Report 1	6/18/16
	16.	Life Cycle Phase II Report 2	6/18/17

 

Lifespan

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]